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Background: Studies have shown a decline in certain cognitive abilities in 
individuals diagnosed with heart disease of any type or etiology. This decline is observed 
as the disease progresses (Muller, Grobbee, Aleman, Bots & van der Schouw, 2006; 
Ernest et al., 2006), as well as after certain interventions, such as coronary artery bypass 
grafting (CABG) and heart valve surgery. In recent years, there has been a great deal of 
emphasis on the beneficial effects of pomegranate on health, including diseases of the 
brain and the heart. Few, however, have explored the impact of pomegranate on cognitive 
functions.  Thus, the current pilot study is unique in its exploration of the effects of 
pomegranate on various health parameters and its possible effectiveness in reducing 
cognitive declines, specifically memory, after cardiac surgery. Methods: The sample 
consisted of 10 patients, who had undergone elective, on-pump, normothermic cardiac 
surgery (CABG and/or valve surgery).  Participants in the treatment group were given 
two pomegranate (PomX) capsules (1000mg each). Participants in the placebo group 
were given two placebo capsules. These capsules were taken daily starting one week 
before and continued to 6 weeks after surgery. Subjects were administered a 
comprehensive battery of neuropsychological tests at each testing session (1 week before 
surgery, 2 weeks after surgery and 6 weeks after surgery); however, those tests only 
assessing memory functions were selected. Results: Results revealed that the treatment 
 xiii 
and placebo groups performed similarly at time 3; however, the critical time period of 
interpatient variability seems to be from time 1 to time 2 (with higher incidences of 
clinical impairments for the placebo group), particularly with visual memory measures. 
Conclusions: Results suggest that there are fewer incidences of memory impairments 
from time 1 to time 2 for individuals that supplemented their treatment with pomegranate 
suggesting that the contents contained in pomegranate may be targeting the factors 
associated with early postoperative dysfunction (i.e. hypoxia, ischemia).    
 
 
 
 1 
CHAPTER ONE 
 
INTRODUCTION 
 
 
Diseases of the heart are the most common cause of adult morbidity and 
mortality, followed by cancer and stroke (Mortality and Morbidity Weekly Report 
[CDC], 2006; Donnelly, 2008). Coronary heart disease (CHD), also called coronary 
artery disease (CAD), is the most common form of heart disease and is caused by the 
accumulation of fatty deposits in the arteries, also known as atherosclerosis. The most 
recent update of the American Heart Association (2007) reveals that in 2004 over 15.8 
million people (approximately 7.3% of the population) were affected by CAD.  Of these 
people, Caucasian males have the highest prevalence of CAD (9.4%), followed by 
African American females (7.8%) and African American males (7.1%). Of all 
cardiovascular diseases, CAD has the highest mortality rate. In 2004, there were 452,300 
deaths caused by CAD, representing the single leading cause of death in the U.S.   
In addition to CAD, valvular disease is a prevalent cause of heart disease and 
mortality. Valvular heart disease describes cardiac dysfunction that is caused by 
functional or structural abnormalities in the heart valves (aortic, mitral, tricuspid and 
pulmonic) (Otto, 2004). This disease can be congenital or acquired later in life through 
age-related degenerative processes, mechanical injury, drug or toxin-related injury, or 
systemic disease-related processes (Donnelly, 2008). At the beginning of the twenty-first 
century, the prevalence of this disease in the U.S. population was estimated to be more 
than 5 million people (Goldbarg, Elmariah, Miller & Fuster, 2007). According to the 
American Heart Association (2006), valvular heart disease is responsible for 20,000 
deaths in the US and a contributing factor in 42,000 deaths each year. Out of these cases, 
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63 percent involved disorders of the aortic valve and 14 percent involved the mitral 
valve. However, deaths due to pulmonic and tricuspid valve disorders are rare.  
 Studies have shown a decline in certain cognitive abilities in individuals 
diagnosed with heart disease of any type or etiology. This decline is observed as the 
disease progresses (Muller, Grobbee, Aleman, Bots & van der Schouw, 2006; Ernest et 
al., 2006), as well as after certain interventions, such as coronary artery bypass grafting 
(CABG) and heart valve surgery. CABG is a surgical procedure that is used to treat 
individuals with CAD and to relieve angina (Klonoff, Clark, Kavanagh-Gray, Mizgala & 
Munro, 1998). Heart valve surgery is a procedure used to repair or replace damaged heart 
valves. Although the rate of mortality has been reduced with these procedures, there is 
growing concern about the morbidity associated with cardiac surgery. Some of these 
issues include stroke, depression and cognitive difficulties. Research on morbidity issues 
are of increasing importance as they play a role in the pursuit to improve surgical 
outcomes and the quality of life in patients (Symes, Maruff, Ajani & Currie, 2000).Thus, 
increased focus has been lent to the postoperative status of the brain and its cognitive 
functions after cardiac surgery (Selnes, Goldsborough, Borowicz & McKhann, 1999).    
Research suggests that a majority of individuals who undergo CABG experience 
declines in neuropsychological functioning post-operatively. This decline has been 
observed in up to 80% of patients early after surgery, and in up to 30% of patients after 6 
months (Knipp et al., 2004). In particular, a decline is evident with verbal memory, word 
fluency and psychomotor speed (Mosley et al., 2005), visual memory, processing speed 
and executive functioning (Muller et al., 2007), as well as attention (Almeida & Flicker,  
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2001). Although research on cognition after valve surgery has been limited, studies have 
shown cognitive declines postoperatively (Ebert, Walzer, Huth & Herrmann , 2001; Hong 
et al., 2008), specifically with surgery that involves valve replacement compared to valve 
repair (Grimm et al., 2003).  
Although findings on cognitive declines have been consistent in CABG and heart 
valve surgery research, preventive or treatment options for cardiac surgery-related 
cognitive dysfunction have not been examined extensively. In recent years, there has 
been a great deal of emphasis on the beneficial effects of pomegranate on health, 
including diseases of the brain and the heart. Few, however, have explored the impact of 
pomegranate on cognitive functions.  Thus, the current study is unique in its exploration 
of the effects of pomegranate on various health parameters and its possible effectiveness 
in reducing cognitive declines, specifically memory, after cardiac surgery.  
 
Coronary Artery Disease (CAD) and Cognition 
 
Cardiovascular disease (which is the umbrella term for CAD) and dementias such 
as Alzheimer’s disease (AD) are common with increasing age (Muller et al., 2007). 
Recent studies have suggested that cardiovascular disease may promote β-amyloid 
deposition in the brain, a pathology that has incidentally been linked to an increased risk 
for Alzheimer’s disease and its associated cognitive deficits, including memory deficits 
(Launer, Masaki, Petrovitch, Foley & Havlik, 1995). Research has also suggested that a 
decline in cognitive functioning with age may be due, in part, to atherosclerotic changes 
(Aleman, Muller, de Haan & van der Schouw, 2005).  
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Atherosclerosis has been implicated in various subtypes of dementia, suggesting 
that there is an association between atherosclerosis and memory dysfunction (Hofman, et 
al., 1997). Atherosclerosis is a disease affecting the arterial blood vessels in which an 
inflammatory response occurs due to the buildup of macrophage white blood cells and 
low density lipoproteins (LDLs, also known as “bad cholesterol”) (Maton et al., 1993). 
An oxidized LDL forms when the lipoprotein crosses an artery wall and oxygen free 
radicals react with it (Kunitomo, 2007). In order to absorb the oxidized LDL, the body’s 
immune system sends macrophage white blood cells to the artery. However, these 
macrophages cannot process the oxidized LDL, which causes the cells to grow, rupture 
and deposit more oxidized cholesterol onto the artery wall signaling more white blood 
cells to the area. The artery becomes inflamed and the plaque causes the muscle cells to 
enlarge, further causing the formation of a hard cover over the affected area. This leads to 
the narrowing of the arteries, reduced blood flow, increased blood pressure (Maton et al., 
1993), and an increased risk of myocardial infarctions (heart attacks) and ischemic 
strokes.  
 Similar cognitive problems have also been observed in individuals without 
dementia. One study quantified the role of cardiovascular disease in cognitive functioning 
in middle-aged and elderly men. Carotid intima-media thickness (a marker of the extent 
of the atherosclerosis), pulse wave velocity (which reflects arterial stiffness), and ankle-
to-brachial systolic blood pressure (which represents the presence of abnormalities of the 
atherosclerotic vessel wall of the leg arteries), were used as measures of cardiovascular 
disease. In addition, cognitive tests that calculated verbal and visual memory functioning, 
processing speed/capacity, and executive functioning were administered. Results showed 
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that increased intima-media thickness was associated with lower scores on memory tests 
and pulse wave velocity was associated with lower scores on processing capacity and 
executive functioning tests.  It was also found that those subjects with prevalent 
cardiovascular disease had a poorer memory performance and lower scores on general 
mental status tests (e.g., MMSE) compared to the control subjects (Muller et al., 2007). A 
comparable study by Hanon and colleagues examined the relationship between arterial 
stiffness [measured by carotid-femoral pulse wave velocity (PVW)] and cognitive 
function in a group of elderly participants reporting memory loss. A significant 
association was observed between PVW and cognitive status. Specifically, they found 
that PVW was higher in those individuals with mild cognitive impairment than in those 
individuals without cognitive impairment, suggesting that functional changes in the 
arterial system can affect cognitive functioning and may be involved in the onset of 
dementia (Hanon et al., 2005).   
Some conditions are considered to put individuals at greater risk for developing 
CAD. Research has shown several risk factors to be associated with CAD, such as total 
cholesterol, LDL cholesterol levels, HDL cholesterol levels, diabetes, blood pressure and 
smoking (Gordon, Castelli, Hjortland, Kannel, & Dawber, 1977; Gordon & Kannel, 
1982). A prospective study utilized a prediction model to determine the risk factors that 
predict CAD in 2,489 men and 2,856 women. During the 12 years of follow-up, 383 men 
and 227 women developed CAD.  Development of CAD was significantly associated 
with blood pressure (hypertension), total cholesterol, LDL cholesterol, and HDL 
cholesterol. This suggests that these risk factors significantly predict CAD (Wilson et al., 
1998).  
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Studies have shown many of these risk factors for CAD are also associated with 
cognitive declines. For example, a number of studies have examined the effects of 
chronic hypertension on cognitive function and have indicated a positive relationship 
between hypertension in midlife and the onset of cognitive decline 15-25 years later 
(Elias, Wolf, D’Agostino, Cobb & White, 1993; Launer et al., 1995; Skoog et al., 1996; 
Kilander, Nyman, Boberg, Hansson, & Lithell 1998a; Swan, Carmelli & Larue, 1998a; 
Launer, 2002; Kivipelto et al., 2006). Cholesterol level and its effect on memory 
disorders such as dementia has also been studied extensively. Research has shown that 
there is an association between high cholesterol levels and dementia in middle aged 
individuals (Notkola et al., 1998; Kivipelto et al., 2006; Moroney et al., 1999). These 
results illustrate that memory functions may be particularly vulnerable to decline in CAD.  
In sum, CAD may initiate β-amyloid deposition and atherosclerosis, conditions 
which have been implicated in memory disorders such as dementia.  Memory problems 
have also been linked to many of the risk factors for CAD (i.e., hypertension, 
cholesterol).  Therefore, it is reasonable to presume that memory problems would be 
among the most likely cognitive deficits observed in those with severe, advanced heart 
disease.  Identifiable interventions which reduce β-amyloid deposition, atherosclerosis, 
hypertension and cholesterol may thus be effective at minimizing consequential memory 
problems.   
Coronary Artery Bypass Grafting (CABG) 
Coronary artery bypass grafting (CABG) is a surgical procedure used in the 
treatment of ischemic heart disease and to relieve angina (Symes et al., 2000). It has been 
found to be an effective treatment for patients with CAD, allowing sufficient blood flow 
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so that oxygen and nutrients can be delivered to the heart. The purpose of CABG is to 
restore the blood flow to areas of the heart muscle that receive an insufficient amount of 
blood and oxygen due to the narrowing of the arteries. During CABG, the left internal 
thoracic artery and the right internal thoracic artery are used for the bypass. If additional 
bypasses are required, a portion of the saphenous vein from the patient’s leg or the radial 
artery from the forearm can be used as well. This vein or artery is used as a graft by 
attaching it at one end to the aorta. The other end is sewn to an opening in the coronary 
artery, beyond the blockage. The graft creates a detour that allows the blood to go around 
the blockage, improving the blood supply to the heart. This entire process may be done 
with or without a heart-lung machine. The utilization of the heart-lung machine to 
perform cardiopulmonary bypass is referred to as “on-pump,” and not utilizing the heart-
lung machine to perform cardiopulmonary bypass is referred to as “off-pump.” With the 
heart-lung machine, the heart is stopped. The oxygen-poor blood is diverted to the 
machine. The machine oxygenates the blood by removing the carbon dioxide and then the 
oxygenated blood is returned to the heart (Horowitz, 1988).  
CABG and Neuropsychological Functioning  
Many studies have examined the potential effects of CABG on 
neuropsychological functioning. Most of these studies have examined cognitive domains 
such as memory, visuo-spatial perception, psychomotor speed, attention, executive 
function and affect (McKhann et al, 2005; Knipp et al, 2004; Selnes, McKhann, 
Borowicz & Grega, 2006). In a review by Selnes et al. (2006), significant early declines 
in memory, psychomotor speed, executive functions and visuo-spatial abilities have been 
observed in various studies. Notably most of the patients return to their baseline cognitive 
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functioning between 3 to 12 weeks. Along with objective declines in memory, subjective 
declines in memory have been reported as well. Subjective memory complaints are the 
most common grievances reported a few weeks after CABG surgery (Selnes et al., 1999). 
However, until recently, subjective memory complaints were not a focus of CABG 
research due to premature conclusions that subjective cognitive changes are more closely 
associated with depressed mood than objective cognitive dysfunction. Selnes and 
colleagues compared CABG patients with nonsurgical patients, who are at risk for 
coronary artery disease, on their self-reported memory symptoms over a period of 3 and 
12 months. The results showed that the frequency of self-reported changes (declines) in 
memory, personality and reading books at 3 months was significantly greater in CABG 
patients than the control group. After controlling for depression, the risk for self-reported 
memory changes was 5 times higher in the CABG patients compared to the control 
group. In addition, the risk of developing new memory problems between 3 months and 
12 months was 2.5 times higher in the CABG group compared to the nonsurgical controls 
(Selnes et al., 2004). Therefore, the study suggests that subjective memory complaints are 
not due to depression and are consistent with objective findings of memory declines after 
CABG.  
Although research on early postoperative cognitive outcome has shown consistent 
results, there have been some inconsistencies reported in studies examining long term 
cognition (1-5 years) after CABG. Studies have reported that motor functions and 
psychomotor speed continue to be affected by CABG five years later (Selnes et al, 2006; 
Stygall et al., 2003). In contrast, declines in verbal learning and memory seem to 
diminish after five years (Stygall et al., 2003). In a small study from Germany, 
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researchers followed up on an initial cohort of patients after CABG. They were retested 
between 32 and 65 months later (median latency 55 months). A significant global decline 
was not reported in any of the patients (Mullges, Babin-Ebell, Reents & Toyka, 2002).  
However, 4 patients (8%) were one standard deviation below their baseline functioning 
on 2 tests. Sixteen patients (31%) had lower follow-up test scores on one test and 46 
(88%) had better results in at least one of the tests. In contrast, another study reported that 
42% of patients out of the 62% of patients that were available for follow-up had a decline 
on a global measure of cognition five years after CABG. These investigators attributed 
these late cognitive declines to old age, fewer years of education, and higher baseline 
score (and therefore, possibly regression to the mean). Importantly, those patients without 
cognitive impairment at discharge (7 days post-CABG) remained above their baseline 
level of cognitive functioning when examined five years later; however, those patients 
with cognitive impairment at discharge showed a marked decline from their baseline 
level of cognitive functioning five years later (Newman et al., 2001). Conflicting results 
may reflect different underlying mechanisms of deficit. 
Physiological Mechanisms 
One proposed mechanism for postoperative cognitive decline is cerebral ischemia. 
Cerebral ischemia is a lack of blood supply to areas of the brain, which may be due to 
hypoperfusion of the brain secondary to CAD itself or it may be due to focal occlusion 
(stroke) by microembolic particles released into the vasculature during surgery (Schmitz, 
et al, 2003).  The incidence of stroke in CABG patients is 0.8-5.2% and studies have 
shown emboli strokes to be the most common type (Gotesman & Wityk, 2006). 
Postoperative cerebral ischemic injury can be assessed using diffusion-weighted 
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magnetic resonance imaging (MRI). MRI studies have shown that there are new focal 
lesions after surgery in 21-45% of patients. One study examined the effects of CABG on 
new postoperative cerebral ischemic lesions. The sample consisted of 101 patients 
undergoing on-pump and off-pump CABG surgery. The results revealed that 3-months 
postoperatively, nine on-pump patients and four off-pump patients had one or more new 
lesions, with more lesions in the middle cerebral artery territory (Lund et al, 2005). 
Another similar study found 45% of the patients to have 32 new ischemic lesions. Of 
these patients 62% had at least 2 new lesions (Knipp et al., 2004). Barber et al. (2008) 
found that 100% of patients with postoperative lesions and 35% of patients without 
lesions demonstrated cognitive declines. Additionally, the study revealed an association 
between the number of abnormal cognitive tests and the number and size of the lesions 
(termed “ischemic burden”). Hypoxia, which often occurs in conjunction with ischemia, 
is another proposed mechanism for post-operative cognitive dysfunction. Cerebral 
hypoxia is a lack of oxygen to the brain despite adequate blood flow (Kolb & Wishaw, 
1996).  
Recent studies have shown that hippocampal structures are directly impacted by 
hypoxia (Browne, Halligan, Wade & Taggart, 2003). Research findings indicate that the 
hippocampus contains highly vulnerable and highly resistant populations of cells 
(Martone, Hu & Ellisman, 2000). An episode of transient ischemia for 10-15 minutes, for 
example, creates a hypoxic state that leads to selective cell death in the CA1 pyramidal 
cells of the hippocampus, which are highly vulnerable to damage under such conditions 
(Schmidt-Kastner & Freund, 1991). One study examined the relationship between 
CABG, postoperative hypoxia, and cognitive function. The sample consisted of 115 
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patients undergoing CABG. Using arterial blood gas measurements, they found that five 
days after CABG, there was a significant correlation between postoperative cognitive 
dysfunction (calculated using a composite cognitive index score) and lower postoperative 
blood gas levels (Browne et al., 2003).  
A separate study examined the effects of CABG (on pump and off pump) on 
cognitive functions and cerebral perfusion (blood flow to the brain) in 65 patients with 
CAD using single photon emission computed tomography (SPECT) imaging that 
captures regional cerebral blood flow images.  SPECT and neuropsychological tests were 
performed one day before surgery, 10-14 days after surgery and six months after surgery. 
Of these patients, 22 patients underwent on pump, normothermic CABG surgery (group 
1), 21 patients underwent on pump normothermic CABG surgery and were administered 
the drug instenon (“Nycomed,” a drug that helps with cerebral perfusion and may prevent 
ischemic and hypoxic cerebral damage) (group 2), and 22 patients underwent off pump 
CABG surgery (group 3). Results revealed that in 68% of the patients, there was a 
decrease in the regional cerebral blood flow in the early postoperative period. Moreover, 
96% of those in group 1, 61% of those in group 2, and 54% of those in group 3 
experienced neuropsychological deficits in the early period after CABG. These patients 
showed significant impairments in the Trail Making Test, Rey Auditory Verbal Learning 
Test and the Complex Figure Test, all of which are primarily executive functioning and 
memory tasks. They also found that the decline in visual memory correlated with a 
decrease in blood flow in the early postoperative period. In the six-month follow-up, 
researchers found that brain perfusion was lower than the baseline in 55% of the patients.  
An improvement of immediate verbal memory correlated with an increase in blood flow 
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6 months after surgery (Chernov, Efimova, Efimova, Akhmedov & Lishmanov, 2006).  
After six months, the incidence of cognitive decline decreased to 55% in all of the cases 
combined. Not only does this study implicate cerebral perfusion as one of the causes of 
cognitive dysfunction, it also suggests that administered agents, such as instenon, which 
improves cerebral perfusion may serve to prevent decline or improve cognitive 
functioning. Like instenon, other preventative treatments such as pomegranate may also 
reduce ischemic and hypoxic cerebral damage after cardiac surgery, and thus play a role 
in reducing postoperative cognitive deficit. Neuron loss has been examined as a potential 
mechanism of post-CABG cognitive deficit as well.  Rasmussen, Sperling, Abildstrom 
and Moller (2002) administered neuropsychological tests and measured neuron loss using 
SPECT in 15 patients undergoing CABG surgery. Neuropsychological testing was 
performed before surgery, postoperatively at discharge and 3 months after surgery. 
SPECT imaging was performed before surgery and 3 months after surgery. To measure 
neuron loss, subjects were given iomazenil, a drug that has a binding affinity for 
benzodiazepine receptors, and then density of the benzodiazepine receptors in the 
cerebral cortex was measured using SPECT. Benzodiazepine receptor density is a 
“measure of the number of GABAergic synapses in the cerebral cortex and is therefore 
assumed to indicate the intactness of cortical neurons” (pg. 1579). Cognitive dysfunction 
was found in 46.7% of patients at discharge from the hospital. Furthermore, there was a 
significant decrease in the density of neurons in the frontal cortex and in the left temporal 
lobe after CABG. However, the SPECT scan results did not correlate with performance 
on neuropsychological measures of memory, sensorimotor speed and cognitive 
flexibility. This suggests that there may be other causes for the cognitive dysfunction and 
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it may not be solely due to the loss of neuron receptors (Rasmussen, Sperling, Abildstrom 
& Moller, 2002).  
Surgical Variables 
Although the results have been mixed about the etiology of neuropsychological 
impairment after CABG, it has been hypothesized that the use of the heart-lung machine 
to conduct the cardiopulmonary bypass is a cause of cerebral injury (Roach et al., 1996). 
With the use of a heart-lung machine, cardiopulmonary bypass diverts blood flow to an 
extracorporeal circuit that maintains sufficient circulation and respiration. It basically 
replaces the heart and lungs in order to assist with the heart surgery (Casthely & 
Bregman, 1991). To avoid the morbidity associated with the on-pump technique, some 
surgeons are performing the off-pump technique. In this technique, a stabilizing device is 
used on the “beating” heart allowing the surgeon to work on the heart without the 
machine (Mitka, 2004).  
One study demonstrated that there is a higher embolic load in those undergoing 
on-pump surgery than those undergoing off-pump surgery (Stroobant, Van Nooten, 
Belleghen & Vingerhoets, 2005). Embolic load refers to the number of cerebral emboli 
that travel through the blood stream, and potentially lodge in and block a blood vessel. 
Embolic load is calculated by counting and measuring the diameter, length and volume of 
the emboli (Brown, Moody, Challa, Stump & Hammon, 2000). An emboli can be a blood 
clot, fat, oil, bubble of air, or a mass of cells which is brought through the blood from a 
large vessel. The emboli is pushed into a smaller vessel where it blocks circulation. This 
may cause cerebral ischemia in which there is an insufficient supply of blood to the brain. 
This may lead to stroke or there may be a gradual decrease in blood flow causing brain 
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damage or death (Kolb & Wishaw, 1996). While there is some evidence of less 
neuropsychological impairment in the immediate postoperative period in those patients 
undergoing off-pump surgery (Diegeler et al.,2000; Zamvar et al., 2002), significant 
differences between off-pump and on-pump surgery in longitudinal cognitive outcomes 
have not been observed (Lund et al., 2005; Van Dijk et al., 2002). 
There has also been considerable variability in surgical procedures within on-
pump surgery such as cross-clamping technique, degree of hypothermia, and rate of 
rewarming that have been implicated as the causes of cognitive declines after CABG 
(Selnes & McKhann, 2005). Majority of the studies have examined differences in 
neuropsychological functioning in normothermic versus hypothermic cardiopulmonary 
bypass. The normothermic technique involves keeping the blood temperature at 
approximately 37°C as it passes through the extracorporeal circuit. The mild hypothermic 
technique involves keeping the blood temperature approximately between 32-34°C 
(Grimm et al., 2000). The hypothermic technique has been used in order to reduce 
oxygen and glucose consumption during cardiopulmonary bypass thereby protecting the 
cells from hypoxic ischemia (Casthely & Bregman, 1991). Some investigators have 
reported that they were unable to reveal an effect of systemic temperature on 
neuropsychological functioning (Grigore et al., 2001). Another study found that cognitive 
impairment was more prominent in patients undergoing mild hypothermia 
cardiopulmonary bypass (Grimm et al., 2000). On the other hand, other investigators 
have found that mild hypothermia has neuroprotective effects and there is less cognitive 
impairment compared to normothermic cardiopulmonary bypass (Kadoi, Saito,Takahashi, 
Fujita & Goto, 2004; Nathan, Wells, Munson & Wozny, 2001).  Overall, surgical 
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techniques or modifications have not consistently controlled for cognitive impairment. 
Thus, there is a need and opportunity to minimize cognitive impairment via some other 
methodology/intervention that is perhaps not surgical.  
Certain perioperative events, such as cardiopulmonary bypass time, have also 
been implicated as a cause of cognitive impairment after CABG. One study examined the 
asymmetry of cerebral embolic load and its effects on cognitive functioning found that 
CABG patients had a decline in verbal memory which was associated with 
cardiopulmonary bypass time, but not with embolic load (Bokeriia et al., 2007). Yet, 
other studies examining perioperative factors such as anesthesia time and surgery time 
have found mixed results in relation to cognitive declines. Studies have shown a 
postoperative cognitive decline in older adults after receiving general anesthesia during 
cardiac and non-cardiac surgery (Anwer, Swelem, el-Sheshai & Moustafa, 2006; 
Rasmussen et al., 2003), particularly in the area of memory (Williams-Russo, Sharrock, 
Mattis, Szatrowski & Charlson, 1995). Similarly, Moller et al. (1998) found that the 
duration of anesthesia was a risk factor for early postoperative cognitive dysfunction. 
However, one study examined elderly patients undergoing non-cardiac surgery under 
general anesthesia and their cognitive functioning after surgery. They found that the 
duration of anesthesia did not predict short-term or long-term change in cognitive 
functioning (Dijkstra, Houx & Jolles, 1999). A study by Ille and colleagues (2007) 
examined patient-related and surgery-related risk factors on cognitive performance. The 
study included patients that were undergoing cardiac surgery, including coronary artery 
bypass grafting. Results revealed that for elderly patients, older age, preexisting medical 
 16 
risk factors, and surgery duration were the most important factors influencing their 
cognitive performance.  
Individual Differences 
Individual factors such as age and education have also been examined in CABG 
studies to determine whether these variables are associated with postoperative cognitive 
dysfunction. Many of the studies have shown that age, specifically increasing age, is 
associated with postoperative cognitive dysfunction (Tuman, McCarthy, Najafi & 
Ivankovich, 1992; Newman et al., 1994). Moller and colleagues (1998) found that age 
may be a risk factor for postoperative cognitive dysfunction 3 months postoperatively, 
particularly in the areas of executive functioning and memory.  
 Years of education of CABG patients has also been examined in many studies and 
has been found to be associated with cognitive decline (Moller et al., 1998; Newman et 
al., 2004). A study by Ho and colleagues (2004) examined various predictors of cognitive 
decline after CABG. They found that many medical variables as well as education were 
associated with cognitive decline 6 months post-CABG. Specifically, the more years of 
education the patients had, the less cognitive decline they had. Another study by Dupuis 
and colleagues (2006) examined the cognitive performance of patients before and after 
CABG, while controlling for age and gender variables. Results revealed that patients with 
less than a high school education had greater cognitive declines on tasks of 
attention/concentration, verbal fluency, and logical/verbal memory. However, there was 
one study which found that education was not a predictor of cognitive change (Selnes et 
al., 1999). In sum, cognitive functions (especially memory) are impacted post-
operatively. Although several hypotheses have been developed to explain postoperative 
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cognitive dysfunction, which include physiological mechanisms (e.g emboli), surgical 
variables (e.g. on-pump vs. off-pump, CPB time, etc.) and individual differences (e.g. age 
and education), findings have been mixed.  
 
Valvular Heart Disease and Cognition 
 Valvular heart disease most commonly affects aortic and mitral valves. 
Specifically, the five most common types of heart valve disease are mitral valve prolapse, 
mitral stenosis, mitral regurgitation, aortic stenosis, and aortic regurgitation. Mitral valve 
prolapse occurs when the leaflets of the valve become enlarged and do not close properly. 
In addition, when the leaflets become enlarged, they bulge into the atrium as the heart 
contracts and disrupt the blood flow. The mitral valve may also become displaced due to 
the fibrous strings supporting the leaflets becoming stretched and inflamed. Moreover, 
starch-like deposits are observed on the valve. The causes of this condition include 
coronary artery disease and Marfan syndrome. Mitral stenosis is characterized by a 
scarred, rigid, and calcium-hardened valve. In this case, blood cannot flow forward easily 
and pressure and fluid build-up are transmitted back to the lungs. The etiology of this 
condition is rheumatic fever, connective tissue disorders and tumors. In mitral 
regurgitation, or mitral insufficiency, the valve does not close properly and the blood 
leaks backward into the atrium. This occurs when the muscles that control the closing of 
the valve malfunction, the fibrous strings supporting the leaflets rupture, or if the valve 
degenerates. The cause of this condition includes rheumatic fever, mitral valve prolapse, 
coronary artery disease, and connective tissue disease. Aortic stenosis is characterized by 
valve degeneration and calcification, often leading to slowed blood flow. The etiology of 
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this condition includes congenital abnormalities, coronary artery disease, and rheumatic 
fever. Aortic regurgitation occurs when the valve does not close properly and blood leaks 
back into the ventricle. The causes of this condition include congenital abnormalities, 
endocarditis, rheumatic fever, connective tissue disorder and aortic stenosis (PDR 
Network, 2010).  
Although the etiology of the two types of heart disease may be different, there are 
certain commonalities between valvular heart disease and coronary artery disease. 
Studies have found a strong association between these two diseases and have shown that 
50% of valve patients have coronary artery disease (Mautner & Roberts, 1992; Peltier et 
al., 2003). Histopathologic evidence has also suggested that lesions in aortic valves is a 
process that is similar to atherosclerosis (Rajamannan, et al., 2002). Specifically, calcific 
aortic stenosis is mediated by a chronic inflammatory disease process that includes 
lipoproteins, lipids, T-lymphocytes, macrophages, and foam cells (VanAuker, 2007; Li, 
Hu, Liu, Tang & Huang, 2007). One study examined the incidence of coronary 
atherosclerosis in patients with acquired valve disorders (aortic and mitral valve). They 
found that patients with aortic valve disease had significant coronary lesions compared to 
patients with mitral valve disease (36% vs. 12.8%), suggesting that the high prevalence of 
atherosclerotic risk factors in patients with aortic valve disease may be similar to that of 
coronary artery disease (Zapolski, et al., 2004).  Given the aforementioned association 
between atherosclerosis and cognitive functioning (and memory in particular), it is 
reasonable to assume memory functioning in those with valvular disease may be similarly 
impacted by heart disease and resulting surgical intervention. 
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Heart Valve Surgery (Repair and Replacement) 
Similar to CABG, almost all current valvular surgical procedures require the use 
of the cardiopulmonary bypass machine (Otto 2004). During traditional valve surgery, 
the surgeon makes an incision down the center of the sternum (breastbone) in order to get 
direct access to the heart. There are several ways to repair valves, including separating 
fused valves in order to widen the valve opening, cleaning calcium deposits to allow for 
more flexibility and proper closure of the valves, triangular resectioning (when a portion 
of the floppy leaflet is cut and sewn again so that it is not in the atrium) to allow for 
proper closure, and patching tears or holes in leaflets to ensure proper blood flow and 
prevent leaks. If repair is not an option, the defective valve is removed and another valve 
is sewn. These replacements can be either biological or mechanical. Mechanical valves 
are made of synthetic durable material that is well-tolerated by the body. However, those 
who receive these valves require life-long treatment with a blood-thinning medication 
due to the incidence of blood clots in these patients. Biological valves, on the other hand, 
are made from biological material, including porcine (pig), bovine (cow), and human 
(allografts or homografts). The disadvantage of this type of valve is that it is not durable, 
typically lasting approximately 10 years, and thus often requires replacement. However, 
no blood-thinning medications are required for this type of valve (Gillinov).  
Heart Valve Surgery and Neuropsychological Functioning 
The impact of CABG on neuropsychological functioning has been a popular topic 
of empirical investigation over the past decade or two. However, research in the area of 
valve surgery and neuropsychological functioning is fairly recent and much more limited. 
However, similar etiological factors have been considered. 
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Individual Differences 
As mentioned previously, factors such as hypertension, cholesterol, diabetes, and 
smoking history have been found to be associated with the development of valvular heart 
disease (similar to CABG). Therefore, it would be expected that cognitive declines may 
be due to such factors, as they are in CAD.  
Physiological Mechanisms 
In addition, the cascade of events (i.e., ischemia and oxidative stress) after valve 
surgery has also been shown to greatly impact cognitive performance. For example, 
studies have found rates of postoperative ischemic lesions after valve surgery ranging 
from 29% to 47% (Stolz et al., 2004; Knipp et al., 2005), with higher rates in those 
undergoing aorta valve surgery (Floyd et al., 2006). One study evaluated brain injury in 
valve replacement patients and demonstrated that there were new ischemic lesions. In 
addition, significant declines were noted in the areas of memory, attention and 
information processing. However, postoperative cognitive dysfunction did not correlate 
with the number of lesions (Knipp et al., 2005). Barber and colleagues (2008) found that 
of those patients undergoing valve surgery, 5% had perioperative strokes, 43% had new 
ischemic lesions, and 63% had cognitive decline 6 weeks after surgery. In addition, 
cognitive decline was associated with perioperative ischemia and greater ischemic load 
(Barber et al., 2008).  
 The types of valve replacements (biological valve prostheses versus mechanical 
valve prostheses) have also been an important area of study.  Research has shown that 
mechanical valve prostheses produce significantly more cerebral emboli compared to 
biological valve prostheses (Georgiadis, Grosset, Kelman, Faicheny & Lees, 1994). One 
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study compared cognitive declines in patients undergoing biological valve prostheses and 
mechanical valve prostheses, by means of P300 auditory evoked potentials which is a 
general indicator of neurocognitive functioning and two standard psychometric tests 
(Trailmaking Test part A and MMSE). Results demonstrated that there was significant 
postoperative cognitive decline in both groups. However, there was no significance in 
cognition between patients undergoing mechanical or biological valve prostheses. In 
addition, it was found that postoperative neurocognitive decline was not reversible in 
patients undergoing biological valve prosthesis, but reversible in patients undergoing 
mechanical valve prosthesis. The researchers suggested that these results may have been 
due to the biological valve prosthesis patients being older in age and reversibility was 
determined by the severity of atherosclerosis (Zimpfer et al., 2003). More recently, the 
same researchers examined the long-term impact of mechanical aortic valve replacement 
on neurocognitive function. This study examined three time points (7 days, 4-month and 
3-years postoperatively. As with the earlier study, they found that there were no adverse 
long term effects on neurocognitive function after mechanical aortic valve replacement 
(Zimpfer et al., 2006).  
Grimm and colleagues (2003) compared neurocognitive brain function in patients 
undergoing mechanical mitral valve replacement and mitral valve repair. Neurocognitive 
function was measured by P300 auditory evoked potentials and two neuropsychological 
tests (Trail Making Test Part A and Mini Mental Status Examination). Results showed 
that those patients undergoing mitral valve replacement demonstrated neurocognitive 
damage, while those patients undergoing mitral valve repair did not show such declines 
(Grimm et al., 2003). 
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 One study examined neuropsychological functioning (specifically, attention and 
verbal and nonverbal learning and memory) in patients undergoing CABG and valve 
replacement surgery at three different assessment points (before surgery, approximately a 
week after surgery and a month after surgery). Results showed that both groups did not 
differ from each other at any assessment point (Browndyke et al., 2002). However, 
another similar study found that patients undergoing valve replacement surgery have 
greater neuropsychological declines than CABG patients, particularly in the area of 
learning and memory (Ebert et al., 2001). It has also been suggested that new ischemic 
brain lesions and strokes are more frequent in patients undergoing CABG and valve 
surgery simultaneously, compared to those undergoing only one cardiac procedure 
(Newman et al., 2006).  
 In patients with atherosclerotic lesions, oxidative stress is a common observation. 
More recently, this phenomenon has been examined in patients with calcific aortic 
valvular stenosis. Results of directed studies have shown that there is an increase in 
oxidative stress in calcified regions of stenotic aortic valves. However, it has also been 
found that the mechanisms involved in oxidative stress are different between 
atherosclerotic arteries and stenotic aortic valves. Specifically, a decrease in antioxidant 
enzyme function has been noted in calcified stenotic aortic valves while an increase in 
antioxidant enzyme function has been demonstrated in atherosclerotic arteries (Miller et 
al., 2008). Although the mechanisms are different, the increase in oxidative stress 
suggests that both CAD and valvular disease have a somewhat similar pathology. 
Therefore, interventions which have the potential to reduce oxidative stress may prove 
useful in reducing negative outcomes (including cognitive decline) in both disease states. 
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Overall, valve disease and subsequent valve surgery appears to be associated with 
cognitive declines; however, there is a limited amount of data compared to CAD and 
subsequent CABG surgery.  
In sum, there are common risk factors between the two disease states that may be 
responsible for some of the cognitive declines observed in cardiac patients. Research has 
also shown that the cardiac surgery itself may cause oxidative stress, hypoxia, ischemia 
and embolisms in the brain leading to significant memory dysfunction. According to a 
review conducted by Rasmussen (2006), studies have demonstrated that this 
postoperative cognitive decline is observed in non-cardiac patients, lending further 
support that surgery may be responsible for a major part of the memory dysfunction.  
Given the physiological mechanisms involved in the disease states and the surgeries, 
pomegranate supplementation may lower/reduce these risk factors and prevent such 
memory dysfunction in patients after cardiac surgery as it has been found to have 
beneficial effects on the heart and brain.  
 
Pomegranate 
Epidemiological studies have suggested that consuming fruits and vegetables rich 
with polyphenols could have beneficial effects on health such as a reduced risk of 
cerebrovascular disease and cardiovascular disease (Hertog, Sweetnam, Fehily, Elwood 
& Kromhout, 1997a; Hertog, van Poppel & Verhoeven, 1997b) and a reduced risk of 
certain types of cancer (Heber, 2008). These polyphenols include epigallocatechin-3-
gallate (found in green tea), curcumin (found in turmeric), resveratrol (found in red wine 
and grape juice), quercetin (found in grapefruit), and ellagic acid (found in raspberries 
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and pomegranates). Pomegranates are one of the dietary sources, highly rich in phenols 
compared to other fruits and vegetables, that has gained interest in recent years (Gil, 
Tomas-Barberan, Hess-Pierce, Holcroft & Kedar, 2000). The pomegranate, or Punica 
granatum L., is a fruit that has been cultivated throughout the Mediterranean region, 
Himalayas, Southeast Asia, Iran, East Indies, Africa, California and Arizona. It has been 
used in the ancient times, believed to grant powers of fertility, wealth and luck. It has also 
been highly featured in the art, mythology and ceremonies of various cultures. Not only 
does the pomegranate have ancient historical purposes, but it has also been used to treat a 
range of ailments (Jurenka, 2008). For example, in Ayurvedic medicine, it has been used 
as an antiparasitic agent (Naqvi, Khan & Vohora, 1991) and as a remedy for diarrhea and 
ulcers (Lad & Frawley, 1986). Also, in the Unani system of medicine, practiced in the 
Middle East and India, the pomegranate has been used as a remedy for diabetes (Saxena 
& Vikram, 2004). More recently, however, it has been found to have antiatherogenic 
(protects against the formation of plaques in the arteries), antiproliferative (inhibition of 
cell growth), antioxidative (protects against the effects of free radicals) and anti-
inflammatory (protects against inflammation) properties (Gil et al., 2000; Afaq, Saleem, 
Krueger, Reed & Mukhtar, 2005; Aviram & Dornfeld, 2001).  
The pomegranate’s anti-oxidative properties have been an important focus in 
recent years. Large amounts of dangerous oxidants or free radicals can affect DNA, 
lipids, proteins and carbohydrates causing the production of toxins, alteration of gene 
expression and enzyme activity, and the disruption of the repair process (Sies, 1997; 
Stanner, Hughes, Kelly & Buttriss, 2003). Oxidative stress (an imbalance between 
oxidants and antioxidants) has been shown to alter tissue structure and function in organs 
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such as the heart, blood vessels, lung, kidney, and brain (Azadzoi, Schulman, Aviram & 
Siroky, 2005) and is a metabolic trigger for inflammation and angiogenesis (formation of 
new blood vessels) which are key factors in the initiation and progression of cancer 
(Lansky et al., 2005; Lansky, Harrison, Froom & Jiang, 2005). Oxidative stress has also 
been implicated in the pathophysiology of many chronic diseases such as cardiovascular 
disease, diabetes (Stanner et al., 2003) and neurodegenerative disease (Smith et al., 1991; 
Marcus et al., 1998).  
Biochemical Constituents in Pomegranate 
Over the past decade, there has been considerable progress in finding the 
pharmacological mechanisms and constituents of the pomegranate responsible for its 
numerous health benefits. Pomegranate juice (PJ) contains 124 phytochemicals (also 
known as polyphenols) (Seeram, Schulman & Heber, 2006) such as tannins 
(punicalagins, ellagic acids, gallagic acids), which accounts for 92% of the antioxidant 
activity of the whole fruit (Malik, Afaq, Sarfaraz, Adhami, Syed & Mukhtar, 2005) and 
flavonoids (anthocyanins, catechins), which gives the fruit its red color (Sumner et al., 
2005; Aviram & Dornfeld, 2001; Aviram et al., 2008; Syed, Afaq & Mukhtar, 2007; 
Malik, et al., 2005). The amount of soluble polyphenols in PJ ranges from 0.2-1.0% 
depending on the variety (Gil et al., 2000; Narr, Ayed & Metche, 1996).  
One of the most potent and most researched polyphenols in pomegrantes is ellagic 
acid. Specifically, it has been shown to have powerful anti-cancer and antioxidant 
properties (Falsaperla, Morgia, Tartarone, Ardito & Romano, 2005; Losso, Bansode, 
Trappey, Bawadi & Truax, 2004; Hossoun, Vodhanel & Abushaban, 2004; Bohn, 
Forsyth, Stoner, Reed & Frank, 1998). Therefore, many commercial pomegranate 
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products have been standardized to contain 40% or more ellagic acid (Jurenka, 2008; 
Lansky & Newman, 2007). However, a prominent researcher on the medicinal properties 
of the pomegranate cautions against focusing on ellagic acid and overlooking the possible 
synergistic effects between ellagic acid and other pomegranate constituents (Lansky et 
al., 2005). Several studies have shown support for the synergistic effects of the various 
constituents, such as quercetin and reserveratrol (Mertens-Talcott, Bomser, Romero, 
Talcott & Percival, 2005; Mertens & Percival, 2005; Lansky et al., 2005; Lansky, et al., 
2005), suggesting that there are more health benefits of a combination of constituents. 
 Variations between pomegranate accessions have also been explored. One study 
examined 29 accessions which differed in their peel and aril colors, taste and strength of 
seed shell. It was found that juices prepared from accessions that have a darker aril color 
have a higher antioxidant activity in comparison to accessions that have lighter arils. The 
results also showed that antioxidant levels are 2-fold higher in homogenates prepared 
from the whole fruit in comparison to homogenates prepared with arils alone (Tzulker et 
al., 2007). 
Studies have also shown that the different parts of the pomegranate such as the 
aril, seed, juice, peel, leaf, flower, bark and roots all have therapeutic properties (Aviram 
et al., 2008; Naqvi et al., 1991). Aviram and colleagues analyzed the antiatherogenic 
properties of the various pomegranate parts in vivo and in vitro. They compared the 
peels, arils, seeds and flowers of the pomegranate to whole fruit juice which contains 
constituents from only the arils and outer peel. It was found that in atherosclerotic E° 
mice (created through gene targeting and and develop severe hypercholesterolemia) who 
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consumed pomegranate juice, peels, arils and flowers experienced a decrease in 
atherosclerotic lesions by 44, 39, 6 and 70% respectively (Aviram et al., 2008).  
Safety of Pomegranate Extracts 
Although pomegranates have proven to be beneficial, pharmacokinetic studies 
investigating pomegranate juice have implicated that there may be a concern for potential 
drug-food interactions. Pomegranate juice contains human cytochrome CYP450 enzyme 
inhibitory activity, similar to grapefruit juice which also has also been found to have 
adverse interactions with drugs (Summers, 2006). CYP450 is a human gene which 
catalyzes reactions involved in drug metabolism and synthesis of cholesterol, steroids, 
and other lipids leading to an excess of these drugs in the blood (Smith, Stubbins, Harries 
& Wolf, 1999). However, a recent in vitro study showed that grapefruit juice has greater 
inhibitory potency than pomegranate juice (Kim et al., 2006). In addition, many studies 
have demonstrated the safety of pomegranate juice intake. Studies have noted no toxic 
effects in animals after intake of pomegranate constituents at concentrations that were 
used in folk and traditional medicine (Vidal et al., 2003). 
 In a dose-response study, researchers investigated the potential adverse effects of 
pomegranate fruit extract (PFE) on rats. They administered 0, 60, 240, 600 mg/kg body 
weight/day of PFE for 90 days. Two additional groups received 0 and 600 mg/kg body 
weight/day of PFE for 90 days with a recovery period of 28 days. It was found that, 
compared to the controls, the intake of PFE did not result in any “toxicologically 
significant treatment-related changes” in clinical observations, ophthalmic examinations, 
body weight, organ weights, food consumption, and pathology evaluations (Patel, 
Dadhaniya, Hingorani & Soni, 2008). Cerd and colleagues (2003a) investigated the 
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effects of punicalagin (abundant in pomegranate) in Sprague-Dawley rats with repeated 
oral administration for 37 days. Results showed that there were no toxic effects or 
significant differences between the treatment and control groups. This was also 
confirmed through histopathological analysis of rat organs. More recently, for dietary 
supplement use, a pomegranate polyphenol extract, enriched in ellagitannin content, has 
been prepared using partially juice-pressed whole fruit, seeds and arils. This supplement, 
referred to as POMx, contains the same ellagitannins found in PJ, but does not contain 
the sugars and calories naturally found in the juice. One study examined the safety of this 
supplement and found that there were no adverse events following consumption of 1420 
mg/day (2 capsules) of POMx (Heber et al., 2007).  
Pomegranate Health Benefits 
Heart 
 Early research conducted with pomegranates was primarily related to heart health, 
mostly in the area of atherosclerosis.  
 
Atherosclerosis 
Animal and human studies have examined the effects of pomegranate on the 
prevention and reduction of atherosclerosis. “Macrophage cholesterol accumulation and 
foam cell formation are the hallmarks of early atherosclerosis” (Ross, 1999). Kaplan and 
colleagues investigated the effect of pomegranate juice on macrophage lipid 
peroxidation, cellular cholesterol flux, and development of atherosclerotic lesions in 
applipoprotein E-deficient (E°) mice with advanced atherogenesis. Results showed that 
pomegranate juice significantly reduced macrophage lipid peroxidation, increased 
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cholesterol efflux by 39% compared to controls and reduced atherosclerotic lesion size by 
17%. This suggests pomegranate effectively slowed down the progression of 
atherosclerosis (Kaplan et al., 2001).  
A study by Rosenblat and colleagues investigated the effects of a pomegranate 
byproduct (PBP), which includes the whole pomegranate fruit left after juice preparation, 
on the development of atherosclerosis in apolipoprotein E-deficient (E°) mice. After the 
consumption of PBP, the mice had a significant reduction in atherosclerotic lesion size by 
up to 57%. Consumption of PBP also significantly reduced oxidative stress in the 
macrophages. In addition, oxidized low-level density lipoprotein uptake by the 
macrophages was reduced by 19%. The study concluded that PBP slows down 
atherosclerotic development due to its antioxidant properties (Rosenblat, Volkova, 
Coleman & Aviram, 2006).  
In addition to atherosclerosis, the effects of pomegranate on other heart variables, 
such as myocardial perfusion (blood flow in the heart), has also been examined. Sumner 
and colleagues (2005) examined whether daily consumption of pomegranate juice for 
three months would affect myocardial perfusion (blood flow in the heart) in coronary 
heart disease and stress-induced ischemia (patients had undergone treadmill exercise or 
pharmacologic stress). The results showed that patients who consumed pomegranate juice 
daily (240ml/day) for three months had a decrease in stress-induced ischemia compared 
to the controls who had an increase in stress-induced ischemia. There was an average 
improvement of 17% in myocardial perfusion in the pomegranate juice group and an 
average worsening of 18% in myocardial perfusion in the control group.  
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Hypertension 
There are many risk factors in the development of atherosclerosis. Hypertension is 
one of the known risk factors in the development of atherosclerosis. In addition, it has 
been shown to be a risk factor in valvular heart disease. Hypertensive patients with an 
elevated plasma-renin angiotensin activity have a five-fold increase risk of myocardial 
infarction. Angiotensin converting enzyme (ACE) inhibits the alteration of angiotensin I 
to angiotensin II which is a potent vasoconstrictor. Studies have shown that ACE 
inhibitors reduce mortality and morbidity in patients with myocardial infarction and 
ischemic events in patients with coronary artery disease. One study examined the effects 
of pomegranate juice consumption on blood pressure and on serum angiotensin 
converting enzyme of hypertensive patients. There was a 36% reduction in serum ACE 
activity and a 5% reduction in systolic blood pressure, suggesting that pomegranate juice 
has an inhibitory effect on serum ACE activity which can protect against the 
development of as well as progression of cardiovascular diseases (Aviram & Dornfeld, 
2001).  
 
Diabetes 
Patients with type 1 or type 2 diabetes are at significant risk for coronary artery 
disease, valvular heart disease, stroke, and peripheral arterial disease. Atherosclerosis has 
been implicated in eighty percent of all deaths among diabetic patients. High blood sugar 
(hyperglycemia) reduces natural anti-oxidants and lends to the production of free radicals 
(Rosenblat et al., 2006). In addition, chronic episodes of high levels of blood glucose may 
directly affect insulin’s action in the brain, damaging cells and causing cognitive 
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impairment (Society for Neuroscience, 2008). Insulin and its receptors are located in 
many parts of the brain. They are especially dense in the hippocampus, suggesting that 
diabetes may affect memory performance (Whitmer, 2007). One study investigated the 
effects of pomegranate flower (PGF) extract on hyperglycemia in Zucker diabetic fatty 
(ZDF) rats. Results showed that PGF inhibited the increase of plasma glucose levels in 
glucose-loaded ZDF rats, but had no effect on fasted ZDF rats. PGF also did not lower 
glucose levels in fasted or glucose-loaded Zucker lean (ZL) rats. These results indicated 
that PGF lowers glucose levels by improving the sensitivity of insulin receptors rather 
than promoting secretion of insulin or inhibiting the absorption of glucose (Huang et al., 
2005).  
Brain 
“Brain aging is characterized by the continual concession to battle against insults 
accumulated over the years” (Lau, Bielinski & Joseph, 2007). One of the key insults is 
oxidative stress. Not only has it been implicated in the aging process, but also in several 
diseases including cerebrovascular and neurodegenerative diseases (Cherubini et al., 
2008). In normal aging, cognitive declines result as the brain undergoes morphological 
and functional changes. In neurodegenerative diseases, such as Alzheimer’s disease and 
Parkinson’s disease, these cognitive declines are amplified (Lau et al., 2007).  
 
Alzheimer’s Disease 
Although very few studies have examined the effects of pomegranate juice on the 
brain, the limited research shows some promising results, especially in the areas of 
Alzheimer’s and Parkinson’s disease. Research suggests that diet can affect the risk for 
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Alzheimer’s disease (AD) and modify amyloid-β levels (Aβ) which has been found to be 
the main constituent of the plaques that are deposited in the brains of AD individuals. 
Studies have shown that antioxidant-rich foods may prevent or neutralize the damaging 
effects of free radicals, thereby slowing down the progression of AD (Kostrzewa and 
Segura-Aguilar,2003; Polidori, 2003). One study examined whether dietary 
supplementation with pomegranate juice would affect AD-like pathology and behavior in 
mice. It was found that the PJ-treated mice learned water maze tasks more quickly and 
swam faster than the controls. They also had 50% less accumulation of beta-amyloid and 
plaque load in the hippocampus compared to the mice that received sugar water, 
suggesting that PJ may be neuroprotective (Hartman et al., 2006). Moreover, research has 
demonstrated that hypoxia and reduced blood supply increase the levels of free radicals 
and the amount of beta-amyloid in the brain (Peers et al., 2009). Therefore, it can be 
implicated that pomegranate may have a beneficial effect on the brain and cognitive 
function by way of lessening damage secondary to hypoxia and reduction of beta-
amyloid.  
 
Neonatal Hypoxic-Ischemic Brain Injury 
Other studies have investigated the effects of pomegranate juice on neonatal 
hypoxic-ischemic brain injury in severely preterm and low birth weight babies. This type 
of injury can lead to encephalopathy, seizures, permanent motor impairment, and death 
(Hankins & Speer, 2003; Shevell, 2004; Volpe, 2001; Back, 2001). Two studies 
examined whether supplementing the maternal diet with pomegranate juice would protect 
the neonatal mouse brain from a experimentally induced hypoxic-ischemic insult when 
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compared to pregnant mice that consumed a control beverage. Results showed that there 
was significantly less brain tissue loss (64% decrease) and significantly less hippocampal 
caspase-3 activity (84% decrease) compared to the controls. These results demonstrated 
that pomegranate juice may have an “antioxidant-driven neuroprotective effect” given 
from the mother to the neonate (Loren, Seeram, Schulman & Holtzman, 2005; West, 
Atzeva & Holtzman, 2007). In addition, these results illustrate pomegranate’s potential 
ability to protect against hypoxia. As mentioned previously, hypoxia and ischemia have 
been found to be potential causes of cognitive dysfunction after cardiac surgery. 
Therefore, it may be speculated that pomegranate will reduce hypoxia and ischemia, and 
subsequently, protect against cognitive decline postsurgically.  
Cognition 
 Although no studies have examined the effects of pomegranate juice on cognitive 
functioning in humans, there have been significant findings showing the beneficial effects 
of the polyphenols found in other fruits and berries (which have similar polyphenols as in 
pomegranates) on cognitive functioning. Flavonoids are the most common type and most 
studied of the polyphenols found in the human diet and can be found in fruits, vegetables, 
cereals, tea, wine and fruit juices (Spencer, 2008). Although polyphenols were initially 
explored for their antioxidant activity, there is evidence suggesting that they exhibit an 
array of effects on the brain. Polyphenols from berry supplementation have not only been 
shown to decrease oxidative stress, but have also been found to stimulate changes in gene 
expression and signaling activity (Willis, Shukitt-Hale & Joseph, 2009).  In one study, it 
was found that blueberry supplementation after hippocampal damage by a neurotoxin led 
to an increase in the number of neurons surviving damage and also reduced the number 
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of activated microglia and expression of proinflammatory cytokines in the hippocampus.  
This suggests that the buildup of oxidative species may lead to alterations in microglia 
activation and cytokine expression which may reduce the damage of the neural tissue of 
the hippocampus (Shukitt-Hale et al., 2008). One study demonstrated that polyphenols 
can directly affect microglia activation, leading to a decrease in the amount of cytotoxins 
released by cells (Lau et al., 2007). Specifically, flavonoids have been shown to have the 
ability to interact with a number of neuronal proteins and signaling pathways that assist in 
synapse growth, increase in the density of dendritic spines, and increased membrane 
receptor density, all of which have been associated with the acquisition, consolidation 
and storage of memory (Spencer, 2008). Therefore, flavonoids may improve memory 
functioning.  
Papandreou & colleagues examined the effects of a polyphenol-rich extract of 
blueberries (which contain anthocyanins) on a test of learning and memory in adult Balb-
c mice for 7 days by intraperitoneal administration. Results showed that there was 
significant improvement in learning and memory compared to the control group 
(Papandreou et al., 2008). Another similar study found that not only do flavonoids 
enhance the animal’s spatial memory, but the improvement in memory is associated with 
increased neurogenesis and neuronal spine density in the dentate gyrus of the 
hippocampus, as well as with the up-regulation of genes that are associated with learning 
and memory (van Praag et al., 2007). ). The potential cognitive benefits of flavonoid 
intake were further illustrated in a prospective study of flavonoid intake and cognitive 
decline in 1,640 dementia-free subjects over a ten-year period. It was found that subjects 
in the two higher quartiles of flavonoid intake had better cognitive performance than 
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those individuals in the lower quartile of flavonoid intake. Ten-year follow up revealed 
that subjects with the lowest flavonoid intake lost an average of 2.1 points on the Mini-
Mental Status Exam (MMSE) and subjects in the higher quartiles lost an average of only 
1.2 points on the MMSE (Letteneur, Proust-Lima, Gouge, Dartigues & Barberger-
Gateau, 2007).  
There is empirical support that the phytochemicals found in fruits can cross the 
blood-brain barrier and localize in various parts of the brain.  These regions may 
therefore be affected by phytochemicals which may in turn translate to various 
cognitive/behavioral changes. One study examined whether different polyphenols could 
be found in different areas of the brain following blueberry supplementation in aged rats. 
Several anthocyanins were found most frequently in the hippocampus and cortex in the 
blueberry supplementation group, but similar concentrations were not found in the 
controls supporting the hypothesis that indeed certain polyphenols cross the blood-brain 
barrier and localize in certain areas of the brain. They also found a relationship between 
Morris Water Maze performance (which measures spatial learning and memory) and the 
total number of anthocyanins found in the hippocampus and cortex (Andres-Laceuva et 
al., 2005) suggesting anthocyanins concentration in the hippocampus may directly impact 
learning and memory.  
 In sum, research has revealed that the polyphenols found in pomegranates have 
been beneficial to health and more specifically, to the brain. There is evidence that 
polyphenols in pomegranates prevent or reduce the incidence of certain diseases, as well 
as target some of the factors associated with cardiac surgery and cognitive declines (i.e., 
ischemia, hypoxia, oxidative stress). Studies have also demonstrated that these powerful 
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polyphenols cross the blood-brain-barrier and affect certain regions of the brain such as 
the hippocampus, an important area for learning and memory.  
 
Given the research findings from cardiac surgery and pomegranate studies, it is 
plausible to hypothesize that the consumption of pomegranate may benefit CABG and 
heart valve surgery patients experiencing these declines, specifically in the realm of 
memory.    
 
Aims and Hypotheses 
Aim 1 
 The first aim of the current study is to examine the impact of pomegranate 
supplementation on memory performance after cardiac surgery. This will be examined by 
comparing composite memory scores of a treatment group to the placebo group across 
three testing time points. Composite memory scores will include learning, immediate 
memory, delayed memory, retention and recognition.   
Hypothesis 1 
There will be a greater reduction in each composite memory score across time for 
the placebo group compared to the treatment group.  
Aim 2 
The second aim of this study is to examine the impact of pomegranate on the 
incidence of significant changes in memory performance after cardiac surgery. More 
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specifically, identify the incidence of memory impairment and comparing the incidence 
of memory impairment across groups.  
Hypothesis 2 
The placebo group will have a greater number of individuals with clinically 
significant declines in memory performance, while the treatment group will have a 
greater number of individuals with clinically significant improvements in memory scores. 
 
Conclusions 
 Heart disease is the leading cause of death in the U.S. and has been shown to be 
associated with cognitive declines. Coronary artery bypass grafting and heart valve 
surgery have been employed as treatments to help restore cardiac functioning at an 
optimal level. Although CABG and heart valve surgery have decreased mortality rates 
associated with heart disease, there is evidence of cognitive declines early in the 
postoperative period with some evidence of declines in the late postoperative period.  
One of the cognitive functions consistently reported and objectively shown to decline 
after cardiac surgery is memory (Kesner & Hopkins, 2006). Research on cardiac surgery 
has shown objective, subjective, imaging and histological evidence that memory is 
impacted after cardiac surgery with specific implications of damage to the hippocampus. 
The mechanisms for memory dysfunction may be linked to the pathophysiology of heart 
disease itself, the surgical procedures often used to treat the heart disease, or even 
individual differences of those with heart disease. Nutritional supplements have been 
proven successful in moderating some of these heart disease risk factors, and thus it is 
speculated that they may thereby moderate the negative cognitive consequences of heart 
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disease and surgical interventions as well. Since the ancient times, the pomegranate has 
been shown to have beneficial effects on health. Various studies have suggested that the 
consumption of polyphenols contained in fruits (such as pomegranates) and vegetables 
may target areas of the brain that are important in learning and memory, such as the 
hippocampus.  
Preventive options for the cognitive declines observed after cardiac surgery have 
not been examined extensively. Given the vast literature on the beneficial effects of 
pomegranate on a wide variety of heart and brain functions, this study will aim to 
understand and examine the effects of pomegranate supplementation on memory 
dysfunction after cardiac surgery.  
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CHLAPTER TWO 
 
MATERIALS AND METHODS 
 
 
Participants 
 Ten elective cardiac surgery patients (CABG and/or valve repair/replacement) 
who met eligibility criteria and signed a written informed consent participated in this 
study. Participants had at least six years of education (to assure the appropriate use of the 
standardized neuropsychological tests). They were recruited from the Loma Linda 
University International Heart Institute at the time they presented for a preoperative 
evaluation and scheduled surgery. Participants who had a history of previous cardiac 
surgery, planned concomitant non-coronary procedures, history of allergy to 
pomegranates, history of head injury, neurodegenerative disease or neurologic condition 
with known cognitive impact (e.g., Alzheimer's disease, Muscular Sclerosis), history of 
drug or alcohol abuse, psychiatric disorder (according to DSM-IV diagnostic criteria), 
active renal disease (indicated by a serum creatinine concentration higher than 2.0 mg per 
deciliter), active liver disease, or left ventricular ejection fraction of less than 20% were 
excluded from the study. In order to assure equal sample sizes between groups for the 
initial group of pilot data, patients were alternated to either treatment of placebo group.  
 
Administration of Study Supplement 
Participants in the treatment group were given two pomegranate (PomX) capsules 
(one capsule in the morning and one in the evening). Each of these capsules contained 
1000mg of concentrated extract. Participants in the placebo group were given two 
placebo capsules (one capsule in the morning and one in the evening). These capsules 
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were taken daily starting one week before surgery (when possible, though scheduling and 
recruitment limitations resulted in some subjects starting the supplement between 2 and 6 
days prior to surgery) and continued to 6 weeks after surgery.   
 
Neuropsychological Assessments 
A comprehensive battery of cognitive tests was administered three times during 
the course of each patient’s participation. These tests were administered just prior to the 
first pomegranate pill administration (approximately one week before surgery), two 
weeks after surgery, and 6 weeks after surgery. Trained graduate students in psychology, 
or the licensed clinical psychologist associated with this study performed all cognitive 
assessments under standardized conditions. All examiners and patients were blinded to 
treatment group.  
All subjects were administered a comprehensive battery of neuropsychological 
tests at each testing session.  For the purpose of this study, those tests assessing memory 
functions were selected. The selected measures included the Wechsler Adult Intelligence 
Scale – III (WAIS-III; Digit Span subtest), Hopkins Verbal Learning Test – Revised 
(HVLT-R), Wechsler Memory Scale - III (WMS-III; Logical Memory subtest), and Rey 
Complex Figure Test (RCFT) with Recognition (using the Meyers and Meyers scoring 
system).  Alternate forms of the HVLT-R are available, and were administered using a 
randomization code.  Shortly after initiation of the study, the RCFT (which does not have 
alternate forms) was replaced by the Brief Visuospatial Memory Test (BVMT) (which 
does have alternate forms) in order to reduce potential practice effects.  Alternate forms 
of the BVMT were administered according to a randomization code. Additionally, the 
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Logical Memory subtest, which has no alternate forms nor acceptable replacements, was 
changed from being administered three times (time 1, time 2 and time 3) to two times 
(time 1 and time 3) in order to reduce potential practice effects.  
Information was gathered on a number of biomedical risk factors and 
demographic variables, including prior history of smoking, hypertension, cholesterol, 
diabetes, education, and social support. An IQ estimate was calculated using the sum of 
scaled scores from WAIS-III Vocabulary and Matrix Reasoning subtests (ERSET 
operations manual). 
 
Statistical Analyses 
Analyses were carried out using the SPSS (PASW Statistics 18) statistical 
software package (SPSS, Inc., Chicago, IL).  
Demographic Group Differences 
Group differences on demographics were examined with independent samples t-
tests for continuous data and chi-square (X2) tests for categorical data.  
Memory Scores 
In order to examine differences between the groups on memory dysfunction 
(hypothesis 1), each patient’s raw scores on the selected memory test variables were 
converted into z-scores using normative data (taking into account age and educational 
level). Composite scores were created for each component of memory function, such as 
immediate memory, delayed memory, and retention by summing the z-scores and 
dividing each sum by the number of tests administered for that subject within each 
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domain. Learning and recognition scores, however, were created only using one score 
from one memory test (Hopkins Verbal Learning Test-Revised) as this was the one 
measure that was consistently administered to all the patients that yielded a learning score 
and that included a recognition format.  
Between and Within Group Differences 
A repeated measures analysis of variance (ANOVA) was conducted to examine 
the differences between and within the groups on each of the components of memory. For 
this analysis, group membership (treatment versus placebo) served as the between-
subjects variable, and time (baseline, 2 week post-op and 6 week-post op) served as the 
within-subjects (repeated measures) variable. Paired-samples t-tests were conducted from 
time 1 to time 2, time 2 to time 3, and time 1 to time 3 for each composite measure for 
both treatment and placebo groups in order to examine significant memory changes for 
each specific time period.  
Effect Size and Power 
Given the small sample size, effect sizes were calculated using Cohen’s d 
statistics and power analysis was conducted using the software program called G*Power. 
Post-hoc Analyses 
Post-hoc analyses included paired-samples t-tests which were conducted from 
time 1 to time 2, time 2 to time 3, and time 1 to time 3 for each individual measure for 
both treatment and placebo groups in order to examine significant memory changes for 
each time period.  
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The incidence of memory impairment or improvement (hypothesis 2) was 
examined using each of the composite scores of memory. A change z-score was 
calculated from preoperative (baseline) to 2 week postoperative, from 2 week 
postoperative to 6 week postoperative, and from preoperative to 6 week postoperative. 
Scores that were one standard deviation below or above each individual’s own 
preoperative z-score were considered an impairment or improvement, respectively 
(Kneebone, Andrew, Baker & Knight, 1998). Furthermore, these calculations were 
performed for each individual memory test. In order to examine whether any change 
between time points was attributable to true, clinically significant change rather than 
simply measurement unreliability and practice effects from repeated administration of 
tests, reliable change indices were calculated for each memory measure based on 
formulations from Chelune and colleagues (1993) that took into account quantified 
practice effects and test-retest reliability. This formulation allows you to determine who 
has changed reliably (i.e., more than the unreliability of the measure would suggest might 
happen for 95% of subjects) by seeing if the difference between the follow-up and initial 
scores is more than a certain level.  These indices were only calculated for time 1 to time 
2 as normative data (means, sd, test-retest reliability) were not available for multiple 
testings beyond two. The reliable change index calculations require use of raw scores for 
each patient on each individual measure at each time point, means and standard 
deviations from a normative population on that measure at each time point, and the test-
retest reliability coefficient.  A cut-off (z-) score for significant change (“impairment” if 
the change is in the negative direction, “improvement” if the change is in the positive 
direction) using the reliable change index is most typically set at +/-1.65 standard 
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deviations, as changes greater than this represents more change than might otherwise be 
expected due to the simply unreliability of the measure with repeated administration to 
the same individual. In the absence of appropriate normative data for evaluating reliable 
change from time 2 to time 3, a significant decline/improvement from time 2 to time 3 
was defined as a change of 1.65 or more standard deviations below or above the mean 
raw score for that measure for the entire sample. 
 Additionally, outlier analyses were conducted when applicable. A z-score of +/- 3 
standard deviations from the mean was considered to be an outlier.  
 
Operational Definitions 
Independent Variable 
Time: Neuropsychological tests were conducted on each participant one week 
before surgery, two weeks after surgery and six weeks after surgery.  
Dependent Variables: Tests of Memory Functioning 
Hopkins Verbal Learning Test – Revised (HVLT-R) 
This test is a list-learning task that assesses verbal learning and memory and 
consists of three immediate recall trials, a 20 minute delayed recall trial and a recognition 
trial consisting of 12 words. There is an immediate recall score (total of all three trials), 
learning score (highest of T2 or T3 minus T1), delayed memory score which is the total 
number of words recalled after the delay, and a recognition score which is the total 
number of words recalled in a list of target words and distractors (Benedict, Schretlen, 
Groninger & Brandt, 1998). A retention score representing the percentage of information 
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retained was created using the following formula: {[(learning score – delayed recall 
score) / learning score] x 100} – 100  
Rey Complex Figure Test with Recognition Trial (RCFT) 
This test assesses visuospatial memory and consists of a copy trial, an immediate 
recall trial (3 minutes), a delayed recall trial (30 minutes), and a recognition trial. Scores 
include a copy score (which reflects the accuracy of the original figure and the time 
required to copy the figure), immediate and delayed recall scores (assesses the amount of 
information retained over time) and the number of items correctly and incorrectly 
identified on a recognition task (Rey, 1941; Osterrieth, 1944). A retention score 
representing the percentage of information retained was calculated using the following 
formula: {[(learning score – delayed recall score) / learning score] x 100} – 100.  
Logical Memory Subtest of Wechsler Memory Scales  
This test assesses contextual verbal learning and memory and consists of two 
stories that are read out loud by the examiner. The first story is read once and the second 
story is read twice. Participants are to recall the stories immediately and after a 25-35 
minute delay and are given a yes/no recognition trial following the delays. Scores include 
an immediate recall and delayed recall (reflecting the amount of information retained 
over time) for all the details of both stories, learning score for the second story, and a 
recognition score (Wechsler, 1945). A retention score representing the percentage of 
information retained was created using the following formula: {[(learning score – delayed 
recall score) / learning score] x 100} – 100.  
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Brief Visuospatial Memory Test – Revised (BVMT-R) 
This test assesses visuospatial memory and consists of three trials in which a 
display of 6 figures is presented for 10 seconds and participants are required to draw the 
figures in their correct locations on the page after each trial. They are required to recall 
these figures after a 20 minute delay and are given a yes/no recognition trial following 
the delays. Scores include immediate recall (total of all trials), delayed recall, learning 
and a recognition score (Benedict, Schretlen, Groninger, Dobraski, & Sphritz, 1996). A 
retention score representing the percentage of information retained was created using the 
following formula: {[(learning score – delayed recall score) / learning score] x 100} – 
100.  
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CHAPTER THREE 
RESULTS 
 
 
Demographics 
The placebo group consisted of Caucasians (60%), Asians (20%), and Hispanics 
(20%) with 60% being males and 40% females.  The mean age of the placebo group was 
approximately 70.2 years, the mean number of years of education was 15 years and the 
mean IQ estimate was 106.6. There was a high percentage of individuals with a history of 
high cholesterol (75%) and smoking history (80%). Percentage of individuals with 
hypertension and diabetes were 40% and 20%, respectively (see Table 1). The treatment 
group consisted of Caucasians (60%), Asians (20%), and Hispanics (20%) (all males). 
The mean age of this group was approximately 62.4 years. The mean number of years of 
education was 15.3 years and the mean estimated IQ was 100.6. Of note, there was a 
participant with an IQ estimate of 71. This individual was examined as a possible outlier 
(approaching the 3 standard deviations cut-off used) given his low IQ score. It appeared 
as though his IQ estimate may have been pulled down by a low vocabulary score. 
However, upon closer examination of his scores, all individual measures compared in this 
study revealed that his scores were all within the acceptable range of variability. That is, 
none of his scores were more than 3 standard deviations from the mean. Therefore, this 
individual was not excluded from the study. There was a high percentage of individuals 
with a history of hypertension (100%), high cholesterol (100%) and smoking history  
(80%). Percentage of individuals with diabetes was 60% (see Table 2). There were no 
significant differences between groups on demographic factors such as age, education 
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and estimated IQ.  Additionally, there were no significant differences between groups on 
medical factors, such as cholesterol (p=.24), diabetes (p=.29) and hypertension (p=.07). 
 
 
Table 1 
 
Demographics – Means and Percentages of the Placebo Group 
 
 
 
 
 Mean (s.d.) % 
PLACEBO   
Age (yrs) 70.2 (8.11)  
Education (yrs) 15.0 (2.0)  
IQ estimate 106.6 (14.43)  
Gender (%)   
    Male                 60.0 
    Female                 40.0 
Ethncity (%)   
    Caucasian  60.0 
    Hispanic  20.0 
    Asian  20.0 
Marital Status                      
    Married  100.0 
    Single  0.0 
    Divorced  0.0 
    Widowed  0.0 
Diabetes                 20.0 
Hx of high cholesterol                 75.0 
Hx of hypertension                 40.0 
Hx of smoking                 0.0 
Surgery type   
    CABG  60.0 
    Valve Repair  20.0 
    Valve Repair & Replacement  20.0 
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Table 2 
 
Demographics – Means and Percentages of the Treatment Group 
 
 
 
 
 
Between and Within Group Comparisons 
 A repeated-measures analysis of variance (ANOVAs) was conducted using the 
pre-surgery, two week post-surgery and six week post-surgery composite memory scores 
(immediate memory, delayed memory, learning, retention, and recognition) in order to 
examine differences between and within groups at each time point. ANOVA results for 
 Mean (s.d.) % 
TREATMENT   
Age (yrs) 62.4 (8.6)  
Education (yrs) 15.3 (2.2)  
IQ estimate 100.6 (20.5)  
Gender (%)   
    Male  100.0 
    Female  0.0 
Ethncity (%)   
    Caucasian  60.0 
    Hispanic  20.0 
    Asian  20.0 
Marital Status       
    Married  60.0 
    Single  0.0 
    Divorced  20.0 
    Widowed  0.0 
Diabetes  60.0 
Hx of high cholesterol  100.0 
Hx of hypertension  100.0 
Hx of smoking  80.0 
Surgery type   
    CABG  60.0 
    Valve Replacement & CABG  40.0 
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immediate memory showed no significant difference within groups [F(2,16) = 1.807, 
p=.196], between groups [F(1, 8) = .055, p=.821], and no interaction [F(2,16) = .579, 
p=.572] (see Table 3). ANOVA results for delayed memory showed no significant 
difference within groups; however, the difference was approaching a significant level 
[F(2, 14) = 2.947, p=.085]. There was no significant difference between groups [F(1,7) = 
.002, p=.966] and no interaction [F(2,14) = .753, p=.489] (see Table 4). ANOVA results  
 
Table 3 
 
Analysis of Variance for Composite Immediate Memory pre-surgery, 2 weeks post-
surgery, and 6 weeks post-surgery 
 
 
 
Table 4 
 
Analysis of Variance for Composite Delayed Memory pre-surgery, 2 weeks post-surgery, 
and 6 weeks post-surgery 
Source SS df MS F p Partial Eta 
Squared 
Within-Subjects       
Delayed Memory .845 2 .422 2.947 .085 .296 
Delayed*Group .216 2 .108 .753 .489 .097 
Error 2.007 14 .143    
Between-Subjects       
Intercept .023 1 .023 .005 .944 .001 
Group .008 1 .008 .002 .966 .000 
Source SS df MS F p Partial 
Eta 
Squared 
Within-Subjects       
Immediate 
Memory 
.588 2 .294 1.807 .196 0.184 
Immediate*Group .188 2 .094 .579 .572 .067 
Error 2.606 16 .163    
Between-Subjects       
Intercept .633 1 .633 .244 .635 .030 
Group .142 1 .142 .055 .821 .007 
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for learning showed no significant difference within groups [F(2,14) = .425, p=.662), no 
significant difference between groups [F(1,7) = .513, p=.497], and no interaction [(F(2, 
14) = .969, p =.404] (see Table 5). ANOVA results for retention showed no significant 
difference within groups [F(2,14) = .086, p=.918], no significant difference between 
groups [F(1,7) = 1.793, p=.222] and no interaction [F(2,14) = .860, p = .444] (see Table 
6). ANOVA results for recognition showed no significant differences within groups 
[F(2,16) = 1.05, p=.373], no significant difference between groups [F(1,8) = .686, p = 
.432], and no interaction [F(2,16) = .332, p=.723] (see Table 7).  
 
Table 5 
 
Analysis of Variance for HVLT learning pre-surgery, 2 weeks post-surgery, and 6 weeks 
post-surgery 
Source SS df MS F p Partial Eta 
Squared 
Within-Subjects       
Learning .349 2 .175 .425 .662 .057 
Learning*Group .796 2 .398 .969 .404 .122 
Error 5.75 14 .411    
Between-Subjects       
Intercept .023 1 .023 .014 .909 .002 
Group .832 1 .832 .513 .497 .068 
 
 
Table 6 
 
Analysis of Variance for Composite Retention pre-surgery, 2 weeks post-surgery, and 6 
weeks post-surgery 
Source SS df MS F p Partial 
Eta 
Squared 
Within-Subjects       
Retention 18.384 2 9.192 .086 .918 .012 
Retention*Group 183.096 2 91.548 .860 .444 .109 
Error 1489.541 14 106.396    
Between-Subjects       
Intercept 186649.798 1 186649.798 258.181 .000 .974 
Group 1295.904 1 1295.904 1.793 .222 .204 
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Table 7 
 
Analysis of Variance for Composite Recognition pre-surgery, 2 weeks post-surgery, and 
6 weeks post-surgery 
Source SS df MS F p Partial 
Eta 
Squared 
Within-Subjects       
Recognition 1.413 2 .706 1.05 .373 .116 
Recognition*Group .446 2 .223 .332 .723 .04 
Error 10.76 16 .673    
Between-Subjects       
Intercept 1.240 1 1.240 .389 .550 .046 
Group 2.187 1 2.187 .686 .432 .079 
 
 
 
Paired samples t-tests of each composite memory measure from time 1 to time 2, 
time 2 to time 3, and time 1 to time 3 revealed no significant declines/improvements on 
any composite memory measure for the placebo group. However, an improvement in 
delayed memory for the treatment group from time 1 to time 3 approached significance 
[t(4) = -2.762, p=.05].  
 
Effect Sizes and Power 
 
 Effect sizes, power and required sample size were calculated for composite 
measures at each time point (see Table 8). Effect sizes for immediate memory ranged 
from medium to negligible over time. Delayed memory effect sizes were small and did 
not change over time. Effect sizes for learning ranged from medium to small over time.  
Recognition effect sizes ranged from large to small over time. Retention effect sizes 
ranged from small to very large over time. 
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Table 8  
 
Effect Sizes and Power for Composite Memory Measures 
 
 
 
 
 n 
(control) 
n 
(treatment) 
Control 
mean 
Control 
sd 
Treatment 
mean 
Treatment 
sd 
Effect 
size 
Power Required 
n 
T1 
Immediate 
Memory 
5 5 -.1360 .82827 -.4933 .83605 .48 
(Medium) 
.2986 52 
T2 
Immediate 
Memory 
5 5 -.1547 .80500 -.1440 1.01686 .01 
(Negligible) 
.0501 -- 
T3 
Immediate 
Memory 
5 5 .0613 .91806 -.0047 1.38836 .06 
(Negligible) 
.0537 -- 
T1 Delayed 
Memory 
5 5 -.0520 1.11604 -.3527 .92152 .33 (Small) .1630 110 
T2 Delayed 
Memory 
5 4 -0.274 
 
1.17581 
 
-0.0408 
 
1.44091 
 
.2 (Small) .0906 296 
T3 Delayed 
Memory 
5 5 .1847 1.28965 .3633 1.18944 .16 (Small) .0759 466 
T1 
Learning 
5 5 -.332 1.203 .3900 .96225 .74 
(Medium) 
.651 22 
T2 
Learning 
4 5 -.334 1.07 .1125 .78725 .55 
(Medium) 
.371 36 
T3 
Learning 
5 5 .224 .46495 .115 .64086 .22 (Small) .128 180 
T1 
Retention 
5 5 79.9200 16.22869 83.0733 10.19925 .26 (Small) .1265 160 
T2 
Retention 
5 4 74.5867 26.02112 91.2917 11.85591 .92 (Large) .9028 16 
T3 
Retention 
5 5 75.5667 21.07795 93.6 10.20185 1.22 (Very 
Large) 
.9599 10 
T1 
Recognition 
5 5 .40 .53385 -.4800 1.486 .88 (Large) .8559 14 
T2 
Recognition 
5 5 .10 .74162 -.2200 1.04259 .40 
(Medium) 
.2843 56 
T3 
Recognition 
5 5 -.30 1.56045 -.7200 1.58335 .30 (Small) .1448 74 
 54 
Post-hoc Analyses 
 Although there are limited significant ANOVA and paired samples t-tests results, 
patterns in the illustrations of the composite memory scores suggest otherwise. For 
example, Figure 1 illustrates the composite scores for immediate memory at each time 
point. It is observed that at time 2, there is a sharp improvement compared to pre-
operative scores for the treatment group, but not for the placebo group (the placebo group 
remains relatively stable). However, by time 3, both groups improve and perform 
similarly. Figure 2 illustrates the composite scores for delayed memory at each time 
point. There is an improvement observed for the treatment group at time 2 compared to 
baseline; however, the placebo group shows a decline from baseline at time 2. Similar to 
immediate memory, both groups improve at time 3 and ultimately perform at a similar 
level. On the other hand, Figure 3 reveals a different pattern for learning. The treatment  
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Figure 1. Performance on immediate memory (composite) for placebo and treatment 
groups 
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Figure 2. Performance on delayed memory (composite) for placebo and treatment 
groups 
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Figure 3. Performance on learning (HVLT-R) for placebo and treatment groups 
 
 
 
group declines by time 2, but the placebo group remains relatively stable. Additionally, 
by time 3, the placebo group shows a sharp improvement, while the treatment group 
shows little improvement. Figure 4 illustrates the composite scores for retention at each 
time point. It is observed that at time 2, there is an improvement for the treatment group 
and a decline for the placebo group. Both groups improve at time 3. Figure 5 reveals a 
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different pattern for recognition. By time 2, the treatment group improves and the placebo 
group declines; however, at time 3 both groups decline sharply.  
Paired samples t-tests were conducted for treatment and placebo groups on each 
individual test at each time point to highlight more clearly the nature of deficits after 
cardiac surgery. Although the Bonferroni correction was not applied, it is important to 
note near significance levels.  
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Figure 4. Performance on retention (composite) for placebo and treatment groups 
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Figure 5. Performance on recognition (HVLT-R) for placebo and treatment groups 
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Logical Memory 
For the placebo group, there were no significant differences between time 1 to 
time 2 or time 2 to time 3 on any of the Logical Memory variables (see Tables 9 and 10). 
However, a near significant level was reached from time 1 to time 3 for immediate 
memory [t(4) = -3.87, p=.02], delayed memory [t(3) = -5.0, p=.02], and retention [t(3) = -
-5.98, p = .01] (see Table 11), with better performances at time 3 compared to time 1. For 
the treatment group, a near significant change was reached from time 1 to time 2 for 
immediate memory [t(2) = -3.67, p=.07] (see Table 12), time 2 to time 3 for retention 
[t(2) = -5.96, p=.03] (see Table 13), and time 1 to time 3 for retention [t(4) = -2.69, 
p=.06] (see Table 14), with better performances at the latter time points. 
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Table 9 
 
Paired T-Tests of Individual Measures at t1 and t2 for the Placebo Group 
 
 
 
 
 
 
 Pre-surgery 
raw scores 
2 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 38.5 7.8 51.5 12.0 -4.33 .144 
     Delayed Memory 23.5 3.5 27.5 3.5 -.800 .570 
     Learning 4.5 2.1 1.5 2.1 -- -- 
     Retention 82.8 24.3 77.8 4.0 .347 .787 
       
Hopkins Verbal Learning Test       
     Immediate Memory 24.4 5.81 22.4 5.13 .784 .477 
     Delayed Memory 8.2 3.42 7.2 4.55 1.20 .298 
     Learning 3.2 2.17 3.2 1.92 .000 1 
     Retention 82.2 15.03 65.8 31.9 .489 .651 
     Recognition 11.4 .894 10.8 1.30 1 .374 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 16.5 14.14 15.0 19.1 .429 .742 
     Delayed Memory 15.5 16.97 15.25 17.32 1.0 .50 
     Retention 46.15 42.21 47.7 41.72 -3.08 .20 
     Recognition 18.5 .71 20.0 2.83 -1.0 .50 
       
Brief Visuospatial Memory Test       
     Immediate Memory 11.67 6.51 17.0 7.81 -2.44 .135 
     Delayed Memory 5.67 2.52 6.67 2.08 -1.73 .225 
     Learning 3.33 1.53 5.0 2.0 -1.39 .30 
     Retention 100.0 0 85.67 12.9 1.925 .194 
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Table 10 
 
Paired T-Tests of Individual Measures at t2 and t3 for the Placebo Group 
 
 
 
 2 week post-
surgery raw 
scores 
6 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 51.5 12.02 49.5 2.12 .286 .823 
     Delayed Memory 30 -- 34 -- -- -- 
     Learning 1.5 2.12 2.5 4.95 -.200 .874 
     Retention 75 -- 92 -- -- -- 
       
Hopkins Verbal Learning Test       
     Immediate Memory 22.4 5.13 22 5.43 .279 .794 
     Delayed Memory 7.2 4.55 6.6 3.65 .885 .426 
     Learning 3.2 1.9 4.2 .84 -1.29 .266 
     Retention 75.6 43.8 65.8 31.9 1.31 .260 
     Recognition 10.8 1.3 10.6 1.67 3.03 .854 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 15.0 19.09 12.25 13.08 .647 .634 
     Delayed Memory 15.25 17.32 14.25 15.91 1.0 .50 
     Retention 49.85 43.91 47.7 41.72 1.387 .398 
     Recognition 20.0 2.83 19.0 2.83 -- -- 
       
Brief Visuospatial Memory Test       
     Immediate Memory 17.0 7.81 16.67 8.96 .378 .742 
     Delayed Memory 6.67 2.08 7.0 4.58 -.189 .868 
     Learning 5.0 2.0 4.67 2.89 .164 .885 
     Retention 85.67 12.9 86.67 23.09 -.105 .926 
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Table 11 
 
Paired T-Tests of Individual Measures at t1 and t3 for the Placebo Group 
 
 Pre-surgery 
raw scores 
6 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 39 5.05 49.2 6.14 -3.87 .018 
     Delayed Memory 21.5 4.93 32.5 5.2 -5.00 .015 
     Learning 3.8 2.17 3.8 2.77 .000 1 
     Retention 73.9 9.25 91.5 7.85 -5.98 .009 
       
Hopkins Verbal Learning Test       
     Immediate Memory 24.4 5.8 22 5.4 1.472 .215 
     Delayed Memory 8.2 3.4 6.6 3.6 4.0 .016 
     Learning 3.2 1.92 4.2 .84 -1.41 .230 
     Retention 82.2 15.02 65.8 31.89 1.98 .120 
     Recognition 11.4 .89 10.6 1.67 1.63 .178 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 16.5 14.14 12.25 13.08 .5667 .111 
     Delayed Memory 15.5 16.97 14.25 15.91 1.667 .344 
     Retention 46.15 42.21 47.7 41.72 -4.43 .141 
     Recognition 18.5 .71 19.0 2.83 -.333 .795 
       
Brief Visuospatial Memory Test       
     Immediate Memory 11.67 6.51 16.67 8.96 -1.64 .243 
     Delayed Memory 5.67 2.52 7.0 4.58 -.610 .604 
     Learning 3.33 1.53 4.67 2.89 -1.51 .270 
     Retention 100.0 0.0 86.67 23.09 1.0 .423 
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Table 12 
 
Paired T-Tests of Individual Measures at t1 and t2 for the Treatment Group 
 
 Pre-surgery 
raw scores 
2 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 39.3 6.02 44.7 3.5 -3.67 .067 
     Delayed Memory 26 5.03 26.67 2.9 -.305 .789 
     Learning 6.0 2.65 5.33 3.06 .756 .529 
     Retention 92.7 6.4 82.0 7.8 2.71 .113 
       
Hopkins Verbal Learning Test       
     Immediate Memory 24.6 3.13 23.8 2.59 .625 .566 
     Delayed Memory 10.0 2.45 8.75 2.36 1.67 .194 
     Learning 4.2 1.64 3.2 2.17 1.2 .298 
     Retention 99.5 14.64 88.75 14.64 1.35 .270 
     Recognition 10.8 1.3 10.6 1.14 .343 .749 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 19.25 1.77 24 2.12 -1.73 .334 
     Delayed Memory 18.25 .35 24.25 .35 -12.0 .053 
     Retention 60.05 5.3 93 26.87 -2.16 .276 
     Recognition 20.5 2.12 21.0 1.41 -1.0 .50 
       
Brief Visuospatial Memory Test       
     Immediate Memory 11.0 8.54 16.67 2.89 -.873 .475 
     Delayed Memory 3.67 2.31 7.33 2.31 -1.38 .303 
     Learning 2.67 2.52 3.0 1.0 -.250 .826 
     Retention 82.0 18.52 103.67 19.76 -2.18 .161 
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Table 13 
 
Paired T-Tests of Individual Measures at t2 and t3 for the Treatment Group 
 
 
 2 week post-
surgery raw 
scores 
6 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 44.7 3.51 45.3 9.5 -.154 .892 
     Delayed Memory 26.7 5.03 30.33 7.09 -3.05 .093 
     Learning 5.3 3.1 2.3 .58 1.44 .286 
     Retention 82 7.8 96.3 4.04 -5.96 .027 
       
Hopkins Verbal Learning Test       
     Immediate Memory 23.8 2.59 24.6 5.03 -.384 .721 
     Delayed Memory 8.75 2.36 8.75 2.36 .775 .495 
     Learning 3.2 2.17 4.0 1.0 -.825 .456 
     Retention 88.75 14.64 84.75 27.02 .293 .789 
     Recognition 10.6 1.14 10.4 1.82 .408 .704 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 24.0 2.12 24.25 6.72 -.077 .951 
     Delayed Memory 24.25 .35 26.75 6.01 -.625 .644 
     Retention 93.0 26.87 89.0 19.8 .121 .923 
     Recognition 21.0 1.41 21.5 2.12 -1.0 .50 
       
Brief Visuospatial Memory Test       
     Immediate Memory 16.67 2.89 15.0 1.0 .945 .444 
     Delayed Memory 7.33 2.31 7.33 .58 0.0 1.0 
     Learning 3.0 1.0 4.0 1.0 -1.0 .423 
     Retention 103.67 19.76 105.67 9.81 -1.23 .913 
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Table 14 
 
Paired T-Tests of Individual Measures at t1 and t3 for the Treatment Group 
 
 
  Pre-surgery 
raw scores 
6 week post-
surgery raw 
scores 
 
 Mean Sd Mean Sd t p 
Logical Memory        
     Immediate Memory 39.3 6.02 45.3 9.5 -1.52 .203 
     Delayed Memory 26 5.03 30.33 7.09 -2.06 .108 
     Learning 6.0 2.65 2.3 .58 1.108 .330 
     Retention 92.7 6.4 96.3 4.04 -2.69 .055 
       
Hopkins Verbal Learning Test       
     Immediate Memory 24.6 3.13 24.6 5.03 0.0 1.0 
     Delayed Memory 8.8 3.42 8.6 2.41 .106 .92 
     Learning 4.2 1.64 4.0 1.0 .272 .799 
     Retention 88.4 27.87 87.8 24.38 .031 .977 
     Recognition 10.8 1.3 10.4 1.82 .784 .477 
       
Rey-Osterrieth Complex Figure Test       
     Immediate Memory 19.25 1.77 24.25 6.72 -.833 .558 
     Delayed Memory 18.25 .35 26.75 6.01 -1.89 .310 
     Retention 60.05 5.3 89.0 19.8 -1.63 .350 
     Recognition 20.5 2.12 21.5 2.12 -- -- 
       
Brief Visuospatial Memory Test       
     Immediate Memory 11.0 8.54 15.0 1.0 -.846 .486 
     Delayed Memory 3.67 2.31 7.3 .58 -3.05 .093 
     Learning 2.67 2.52 4.0 1.0 -.658 .578 
     Retention 82.0 18.52 105.67 9.81 -2.0 .184 
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Illustrations of Logical Memory performance revealed variability in the patterns 
of memory. For example, Figures 6 and 7 shows that the treatment group has very little 
improvement in immediate and delayed memory from time 1 to time 2 compared to the 
placebo group. However, from time 2 to time 3, there is a sharper improvement in the 
treatment group compared to the placebo group. Figure 8 illustrates that learning 
decreases for the treatment group at each time point; however, the placebo group 
improves from time 2 to time 3. On the other hand, Figure 9 shows that retention 
increases for the placebo group at each time point; however, retention declines for the 
treatment group from time 1 to time 2, but improves from time 2 to time 3. 
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Figure 6. Logical memory (immediate memory) at each time point by group 
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Figure7. Logical memory (delayed memory) at each time point by group 
 
 
 
 
 
-2.00
-1.00
0.00
1.00
2.00
Time
LM
 L
ea
rn
in
g 
z-
sc
or
es
 (m
ea
ns
)
Placebo
Treatment
Placebo 0.00 -1.00 -0.50
Treatment 0.78 0.67 -0.66
1 2 3
 
Figure 8. Logical memory (learning) at each time point by group 
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Figure 9. Logical memory (retention) at each time point by group 
 
 
Hopkins Verbal Learning Test-Revised 
For the placebo group, there were no significant differences from time 1 to time 2 
or time 2 to time 3 on any of the HVLT-R variables (see Tables 9 and 10). However, a 
near significant decrease was reached from time 1 to time 3 on delayed memory [t(4) = 
4.0, p=.02] (see Table 11). For the treatment group, there were no significant differences 
from time 1 to time 2, time 2 to time 3, or time 1 to time 3 (see Tables 12-14).  
Illustrations of HVLT-R scores revealed variability in the patterns of memory. For 
example, Figure 10 shows less decline on immediate memory in the treatment group 
compared to the placebo group from time 1 to time 2; and, from time 2 to time 3, the 
treatment group improves while the placebo group declines. Figures 11 and 12 illustrate 
declines in delayed memory and retention for both groups at each time point; however, 
slightly less declines are observed for the treatment group. Learning patterns illustrated in 
Figure 13 show that the treatment group declines from time 1 to time 2 while the placebo 
group remains relatively stable. However, from time 2 to time 3, learning sharply 
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improves for the placebo group, but remains relatively stable for the treatment group. 
Figure 14 illustrates that the treatment group improves on recognition from time 1 to time 
2, while the placebo group shows declines. However, both groups decline from time 2 to 
time 3. 
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Figure 10. HVLT-R (immediate memory) at each time point by group 
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Figure 11. HVLT-R (delayed memory) at each time point by group 
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Figure 12. HVLT-R (retention) at each time point by group 
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Figure 13. HVLT-R (learning) at each time point by group 
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Figure 14. HVLT-R (recognition) at each time point by group 
 
 
Rey-Osterrieth Complex Figure Test with Recognition 
For the placebo group, there were no significant differences from time 1 to time 2, 
time 2 to time 3, or time 1 to time 3 (see Tables 9-11). For the treatment group, a near 
significant change was reached from time 1 to time 2 on delayed memory [t(1) = -12.0, 
p=.05] (see Table 12) with better performances from time 1 to  time 2, but no significant 
differences  from time 2 to time 3 or time 1 to time 3 (see Tables 13 and 14).  
Illustrations of RCFT scores largely revealed improvements from time 1 to time 2 
for the treatment group compared to the placebo group in immediate memory, delayed 
memory, and retention (see Figures 15-17). Similarly, from time 2 to time 3, the 
treatment group remained stable or continued to improve for immediate and delayed 
memory (see Figures 15 and 16). However, the treatment and placebo groups showed 
slight declines from time 2 to time 3 on retention (see Figure 17).  Figure 18 illustrates 
improvements in the treatment and placebo groups for recognition from time 1 to time 2; 
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however, the treatment group continued to improve from time 2 to time 3, while the 
placebo group declined. 
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Figure 15. RCFT (immediate memory) at each time point by group 
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Figure 16. RCFT (delayed memory) at each time point by group 
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Figure 17. RCFT (retention) at each time point by group 
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Figure 18. RCFT (recognition) at each time point by group 
 
 
Brief Visuospatial Memory Test-Revised 
For both the placebo and treatment groups, there were no significant differences 
from time 1 to time 2, time 2 to time 3 or time 1 to time 3 (see Tables 9-14). Illustrations 
of BVMT performance revealed variability in the patterns of memory. For example, 
Figure 19 shows improvements in immediate memory from time 1 to time 2 for treatment 
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and placebo groups; however, from time 2 to time 3, the treatment group shows greater 
decline from time 2 to time 3. Figure 20 reveals greater improvements in delayed 
memory for the treatment group compared to the placebo group from time 1 to time 2; 
however, from time 2 to time 3, the treatment group remained relatively stable while the 
placebo group improved slightly. Although the placebo group showed greater 
improvements on learning from time 1 to time 2, the treatment group continued to 
improve from time 2 to time 3 while the placebo group declined (Figure 21).  Figure 22 
illustrates improvements in retention at each time point for the treatment group.  
However, the placebo group declined from time 1 to time 2 and then improved slightly at 
time 3. 
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Figure 19. BVMT (immediate memory) at each time point by group 
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Figure 20. BVMT (delayed memory) at each time point by group 
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Figure 21. BVMT (learning) at each time point by group 
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Figure 22. BVMT (retention) at each time point by group 
 
   
Incidence of Impairment or Improvement 
In order to quantify the incidence of clinical impairment/improvement on memory 
functions, the mean z-score change score was calculated for the treatment and placebo 
groups for each composite score for the components of memory (time 1 to time 2, time 2 
to time 3 and time 1 to time 3). Impairment or improvement was operationally defined as 
a decline or improvement of 1 standard deviation in the individual’s z-score change.  This 
method of defining impairment has been utilized in previous research (Kneebone et. al, 
1998).  
 
Reliable Change Indices 
Reliable change indices (Chelune, et al. 1993) were calculated for most of the 
memory measures (e.g., RCFT immediate memory & delayed memory; HVLT-R 
immediate memory, delayed memory, learning, retention & recognition; and BVMT 
immediate memory & delayed memory) in order to determine if a statistically significant 
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and reliable change in memory performance exists after accounting for expected practice 
effects.  The patterns of performances that showed one group performing worse or better 
than the other on the components of memory for HVLT-R, RCFT, and BVMT remained 
relatively the same from time 1 to time 2 demonstrating that practice effects do not 
account for the changes observed (see Figures 23-25). Independent samples t-tests on 
reliable change indices demonstrated no significant differences between the treatment and 
placebo groups on any of the HVLT-R or BVMT variables; however, the two groups 
differed on RCFT delayed memory performances with better scores for the treatment 
group (p=.07).   
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Figure 23. Reliable change indices (RCI) for HVLT-R memory measures by 
group (time 1 to time 2) 
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Figure 24. Reliable change indices (RCI) for RCFT memory measures by group 
(time 1 to time 2) 
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Figure 25. Reliable change indices (RCI) for BVMT memory measures by group 
(time 1 to time 2) 
 
 
Table 15 illustrates the instances of clinical impairment/improvement over all 
time periods for each memory composite within all the tests. It identifies the number of 
individuals impaired or improved (by time point, group, memory composites, and 
individual tests). Specifically, it shows a significantly greater number of instances of 
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clinical declines for the placebo group and fewer for the treatment group from time 1 to 
time 2 across all memory composites (Χ2 = 4.5; p=.03). More specifically, there were 
individuals who had impairments across all tests (usually more than one test). However, 
from time 2 to time 3 and time 1 to time 3, they are almost similar in the number of 
instances of clinical declines and improvements (Χ2 = .733; p=.39; Χ2 = .06, p=.82 
respectively). Although the instances of impairments are higher in the placebo group than 
the treatment group from time 1 to time 2, it is important to note that the treatment group 
had 2 individuals with clinical impairments compared to the placebo group that had 3 
individuals. From time 2 to time 3, both treatment and placebo groups had 3 individuals 
with clinical impairments in each group. 
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Table 15 
 
Incidences of Memory Performance Declines and Improvements  
 
*Numbers outside the parentheses are the number of individuals that have impairments or 
improvements. Numbers within the parentheses are the actual subject numbers given to 
the patients at the time of testing. 
 
 
 
Outliers 
 Outliers were examined for HVLT-R, BVMT-R and Logical Memory. RCFT 
outliers were not examined given that the two groups only had 2 individuals in each 
 t1-t2 
Treatment 
t1-t2 Placebo t2-t3 
Treatment 
t2-t3 Placebo t1-t3 
Treatment 
t1-t3 Placebo 
 Dec. Imp. Dec.  Imp.  Dec. Imp. Dec. Imp. Dec. Imp. Dec. Imp. 
Composite 
Immediate          1    
Delayed 1        1    
Learning   2 1 1  1 3 1 1 1 2 1 
Retention     1 1 1   2   2 
Recognition 1 1  2  2 1 1  1  1 
Individual Measures 
LM imm.   2 (1,2)    1 (2)    2 (1,4)  
LM del.   1 (2)      1 (9)  4 
(2,3,4,
5) 
 
LM learn      1 (7)  1 (1)  1 (7)  1 (1) 
LM reten.     1 (8)    2 (7,9)  3 
(2,4,5) 
 
RCFT imm.   1 (2)  1 (7)    1 (7)    
RCFT del.   2 (1,2)  1 (7)    1 (7)    
RCFT recog.             
BVMT imm. 1 (10) 1 (9)   1 (9)     2 
(8,10) 
 1 (3) 
BVMT del.  1 (9)    1 (9)  1 (3)    1 (3) 
BVMT learn       1 (4) 1 (3) 1 (9) 1 (8) 1 (4)  
BVMT reten.     1 (8)  1 (4)  2 
(8,10) 
  1 (3) 
HVLT imm.   1 (1)   1 (8)      1 (1) 
HVLT del. 1 (9)  2 (1,3)      1 (6) 2 
(9,10) 
  
HVLT learn             
HVLT reten. 1 (9)  1 (3)  1 (8) 1 (10)  2 (2,4) 2 (6,8) 2 
(9,10) 
 2 (2,3) 
HVLT recog. 1 (10)  2 (1,3)   2 (6,8) 1 (1) 1 (2)  1 (10)  1 (2) 
TOTAL 4 2 12 0 7 6 4 6 11 9 10 8 
Trt.  Decline 22            
Trt. Improve 17            
Pla. Decline 26            
Pla. Improve 14            
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group and the elimination of outliers would not give an accurate picture of the pattern of 
performances. There were no outliers given the criteria mentioned above for Logical 
Memory. For BVMT-R, one outlier was removed for delayed memory. Figure 26 
illustrates the pattern of performances. Notably, the pattern does not change from the 
illustration with the outlier. For HVLT-R, several outliers were removed for delayed 
memory, retention and recognition. The treatment group demonstrates a decline on 
delayed memory from time 1 to time 2; however, the placebo group demonstrates an 
improvement. On the other hand, from time 2 to time 3, the treatment group remains 
relatively stable while the placebo group sharply declines.  For retention, the placebo 
group increases from time 1 to time 2; however, the treatment group decreases from time 
1 to time 2. However, from time 2 to time 3, both groups decline slightly. For 
recognition, both groups decline from time 1 to time 2; however, from time 2 to time 3, 
the placebo group improves while the treatment group remains stable (Figures 27-29). 
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Figure 26. BVMT-R delayed memory (without outliers)  
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Figure 27. HVLT-R delayed memory (without outliers) 
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Figure 28. HVLT-R retention (without outliers) 
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Figure 29. HVLT-R recognition (without outliers) 
 
 
 
 
Effect Sizes 
Given that each of the individuals differed in their baseline scores, it was 
important to take this into account and calculate the effect size of the change scores 
between the groups from time 1 to time 2 period (as the two groups differed most from 
each other during these time periods). Results revealed a very large effect size (1.61-3.19) 
between the groups for each of the memory domains (i.e., immediate memory, delayed 
memory, retention and recognition), with the treatment group performing better at time 2. 
Although the learning effect size showed a very large effect between the groups, the 
placebo group was performing better at time 2 than the treatment group.  
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CHAPTER FOUR 
DISCUSSION 
 
Although many studies have demonstrated significant declines in cognitive 
functioning after cardiac surgery, limited studies have focused on possible preventative 
and treatment options for reducing postoperative cognitive dysfunction. Pomegranate has 
shown promise as a neuroprotective agent against cognitive impairment in animal 
models, but has not been explored in human models of brain disease or injury.  Given 
this, the focus of this study was to examine whether pomegranate might similarly protect 
against memory impairment in individuals with heart disease treated with cardiac 
surgery.  Positive findings have broad implications for individual patients, health, and 
treatments for heart disease.   
 
Demographics  
 Comparison of demographic data for the treatment and placebo groups revealed 
that although there were no detectable significant differences between groups on age, 
education and estimated IQ, the placebo group was older, and had a higher estimated IQ 
compared to the treatment group. Similarly, no detectable significant differences were 
found on medical history variables (e.g., hypertension, cholesterol, diabetes, and smoking 
history); however, it was qualitatively observed that there was a greater number of 
individuals with hypertension, high cholesterol, diabetes, and history of smoking in the 
treatment group.  
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Memory Composites 
The results of the study revealed that there were no significant differences 
between groups in the amount of change in any composite memory component from 
before to after surgery.  The implication of such results is that pomegranate did not have 
a significant effect on memory performance in this sample. No significant memory 
changes were found in any composite memory component for any time period, with the 
exception of the treatment group who performed better on delayed memory at time 3 
when compared to their baseline score. Although research has demonstrated significant 
early cognitive declines after cardiac surgery with some improvement after the early 
period, this study did not support those findings for this sample. Negative findings may 
reflect design limitations such as low power due to too few subjects.  
Visual analyses of the data are intriguing and may suggest developing trends in 
the data not otherwise identified by statistical significance.  In particular, memory 
performance tended to decline very little for both groups, although the literature predicted 
otherwise. Instead, it tended to remain stable and, for some, improved from before to 
after cardiac surgery. This can be explained by the fact that most of these individuals may 
have a moderate to high cognitive reserve (which was not calculated), based on their IQ 
and education. Research has shown high cognitive reserve to be a protective factor in 
cognition (Corral, Rodriguez, Amenedo, Sanchez & Diaz, 2006) and even protective in 
heart disease and cardiac surgery (Ropacki, Bert, Ropacki, Rogers & Stern, 2007). 
Perhaps if there were more subjects with greater variability in cognitive reserve, we may 
have observed a different picture, one that is consistent with the literature. Improvements 
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may be attributed to the better blood flow in the heart and subsequently, the brain after 
surgery.  
Observable trends for the treatment group to improve on memory from before 
surgery (baseline) to after surgery (most notably from baseline to time 2) is in direct 
contrast to the lack of improvement for the placebo group.  Although the exact 
mechanisms of the pomegranate workings cannot be determined, early postoperative 
improvements in memory may indicate that variables associated with the surgery may 
have been acted on by the pomegranate (e.g., hypoxia and ischemia which are often 
observed early postoperatively), thereby protecting some components of memory.  
Similar performances and improvements for both groups from time 2 to time 3 suggest a 
diminished effect of pomegranate, possibly due to the diminishing impact of hypoxia and 
ischemia on memory beyond the immediate postoperative period.   
Further exploration of the results reveals certain patterns within each memory 
composite which are important to note as they may provide a context for understanding 
these emerging differences between groups. More specifically, in the treatment group, a 
sharp improvement in immediate memory is observed early after surgery; however, there 
is only a modest improvement from time 2 to time 3 in this group. A similar pattern is 
observed for delayed memory and retention. However, in the placebo group, relatively 
little change is observed in immediate memory, while decline on delayed memory and a 
decline in retention are observed early after surgery. Yet, similar to the treatment group, 
the placebo group shows improvement from time 2 to time 3. This may further support 
the claim that the pomegranate is acting upon the early postoperative hypoxia associated 
with the surgery, as opposed to the disease state.  
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In order to facilitate the interpretation of the substantive results as opposed to 
relying on statistical significance, the results may also be examined in the context of 
effect size. Calculations of effect size revealed negligible or diminishing effects for most 
of the components of memory (e.g., immediate memory, delayed memory, learning, and 
recognition). Although a couple of the tests (e.g., HVLT-R and BVMT) have alternate 
forms, the other tests do not (Logical Memory and RCFT); thus, practice effects may 
have been differentially impacting results and, moreover, may have skewed the effect 
sizes and power of the measures to detect true changes in memory functioning. 
Additionally, it is important to note that at baseline, there are mostly larger effect sizes 
than at time 2 or time 3 for many of the above mentioned components. This may suggest 
that the two groups differed in their performances on the components of memory at 
baseline, but due to the small sample size, the analyses may not have been able to detect 
statistically significant changes in memory performance. One component of memory 
(retention), in contrast, demonstrated the opposite pattern over time. It is important to 
note that the effect sizes for retention started out small at time 1, but significantly 
increased from time 2 to time 3 suggestive of a relationship between retention and 
treatment effect. Overall, examination of the effect sizes of all of the components 
examined in this study reveals that there may be some relationship between retention and 
the intervention. Since research has implicated the role of the medial temporal lobe and 
hippocampus in episodic memory (see Review – Budson, 2009), we can deduce that 
these are the areas that are being affected after surgery for the placebo and treatment 
groups. Additionally, research on CABG surgery has demonstrated neuronal loss and 
susceptibility for hypoxia in the temporal lobe and more specifically, the hippocampus. 
 86 
However, it may be that pomegranate may be providing some protection from the effects 
of hypoxia leading to better outcomes in retention rates compared to the placebo group.   
Illustrations of learning demonstrate that the placebo group performs better from 
time 1 to time 2 and from time 2 to time 3 compared to the treatment group. This may be 
explained by certain characteristics of the HVLT-R. The HVLT-R learning score is 
considered to be a measure of working memory that requires executive skills including 
organization and strategy (Rudolph et al., 2006). It has been demonstrated that patients 
with frontal lobe lesions fail to utilize memory strategies to enhance the encoding and 
retrieving of information (Baldo and Shimamura, 2002), which may in turn impact the 
ability to freely recall the information. Figure 30 demonstrates that in the current study,  
the placebo group performs better than the treatment group on an attentional/working 
memory task (WAIS-III Digit Span).  Their better executive skill may be a factor 
contributing to the observed learning pattern. Research has also demonstrated an 
association between cardiovascular risk factors and the development of cerebral white 
matter lesions. These lesions have been associated with executive dysfunction (see 
review - Kuo and Lipsitz, 2004). Given that the frequency of individuals with 
hypertension, cholesterol, diabetes and smoking is higher for the treatment group than the 
placebo group, we can speculate that the treatment group may have greater frontal lobe 
impairments compared to the placebo group. Additionally, the mechanism for damage in 
the frontal lobe (related to cardiovascular risk factors), and subsequent learning difficulty, 
may be different from the mechanism for damage occurring after surgery (e.g. transient 
ischemia/hypoxia). Given what we understand about the areas most susceptible to 
hypoxia (e.g. hippocampus), we may be able to speculate that individuals may not benefit  
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Figure 30. Working memory (WAIS-III Digit Span) by group 
 
 
 
from pomegranate supplementation with regards to using strategies to learn (which can 
be considered a frontal lobe function).  
Illustrations of recognition memory performance demonstrate that the treatment 
group performs better from time 1 to time 2 compared to the placebo group, implicating a 
role of pomegranate supplementation in this time frame; however, both groups decline 
sharply from time 2 to time 3. Given this information, it may be possible that there are 
some lasting effects of the surgery or the disease states that is impacting the temporal 
regions. Research has shown that cognitive functions began their return to baseline levels 
after the early postoperative. However, research has also demonstrated that there are 
some individuals that continue to experience long term cognitive declines. This finding 
further supports the idea that the pomegranate is benefiting in the early postoperative 
period, but demonstrating diminishing effects as there are diminishing instances and 
effects of hypoxia over time.  
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Individual Memory Measures 
 In order to further explore the contributions of each neuropsychological test to the 
composite measures of the components of memory, each test was examined over time. 
First, it is important to note that baseline memory functioning on each of the individual 
measures for both the treatment and placebo groups were largely in the average to high 
average ranges with the exception of a visual learning and memory measure (BVMT). 
This exception will be discussed later in the context of the format of the tests.  Moreover, 
although both treatment and placebo groups scored within the average to high average 
range on measures of verbal memory, they performed in the lower to middle range of 
average on a rote/noncontextual verbal memory test (HVLT-R), which was in contrast to 
their performances in the mid to high average range on contextual memory tests (Logical  
Memory, RCFT). Overall, improvements or declines within each of the measures are 
more likely to represent true change given that they are performing as expected (e.g.,  
within the normal range) and there is no instance of regressing to the mean in such a case; 
however, improvements on BVMT on successive testing points could be a function of 
regression to the mean, as this sample was initially impaired at baseline on this measure.  
Logical Memory 
The placebo group had significant improvements on immediate memory, delayed 
memory and retention from time 1 to time 3.  This pattern of consistent improvement 
over time may be a function of cardiac surgery restoring blood flow in the heart which in 
turn affects blood flow to the brain; in such circumstances, it would be expected that at 
least minimal improvements would continue to be made over the observed six week 
period. The treatment group had significant improvements on immediate memory from 
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time 1 to time 2 and on retention from time 2 to time 3 (and time 1 to time 3). However, 
the early postoperative changes (improvements) in immediate memory suggests the 
pomegranate’s impact may be most powerful early after surgery, when the hippocampus 
has perhaps taken the biggest “hit” by surgery. Comparing these two groups, graphically, 
there is variability in the performances. Some of this variability can be contributed to 
practice effects as some patients were administered this test at time 2, while others were 
not (although there were no detectable significant differences, the fact that some tests 
were administered more times than others may create some variability over time).  
Additionally, since some patients were not administered this test at time 2, there is a 
smaller sample size at this point (5 patients instead of 10). Therefore, we may not be 
observing an accurate picture of the treatment effects from time 1 to time 2.  
Hopkins Verbal Learning Test-Revised 
This test was considered to be important in capturing the effects of pomegranate 
as this test was administered to all the patients at each time point (unlike the other tests) 
and had alternate forms. However, graphical illustrations of the results were not as 
expected with a great deal of variability observed in the patterns of the memory process 
for both groups. The placebo group had no significant declines or improvements from 
time 1 to time 2, or time 2 to time 3; however, they did demonstrate significant decline 
from time 1 to time 3 on delayed memory. The treatment group had no significant 
declines or improvements from time 1 to time 2, time 2 to time 3 or time 1 to time 3.  
Since delayed memory scores are a product of initial learning and immediate memory 
(that is, how much can be recalled after a delay is directly dependent upon how much 
information is initially learned and immediately encoded), evaluation of learning and 
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immediate memory scores may inform our understanding of these patterns in delayed 
memory performance.  More specifically, these patterns suggest the observed decline in 
delayed memory for the placebo group stems from diminished learning and immediate 
memory from time 1 to time 2, as evidenced by declines in learning scores and declines 
in immediate memory scores.  This interpretation is further supported in light of similar 
retention scores across the groups – both groups ultimately retained a similar amount of 
the information initially learned, though that amount was less in the placebo group. As 
mentioned previously, HVLT-R not only has a strong memory component, but it also has 
a component that is tapping into the workings of the frontal lobe (e.g. organization of the 
words into categories for easier encoding, and subsequent recall of the information after a 
delay).  Therefore, the findings may be due to contributory effects of the frontal lobe.  
Rey-Osterrieth Complex Figure Test 
The placebo group had no significant declines or improvements from time 1 to 
time 2, time 2 to time 3 or time 1 to time 3 on any of the components of memory. The 
treatment group had a significant improvement from time 1 to time 2 on delayed 
memory. Illustrations of RCFT performance demonstrated less variability in the patterns 
of the components of memory (although some variability still existed) than the above 
mentioned tests with largely better performances for the treatment group. It is observed 
that the treatment group has better immediate memory from time 1 to time 2, suggesting 
that they may be learning the information in a more effective way compared to the 
placebo group (although there is no way to calculate a learning score for RCFT). It is 
important to note that the task already provides a context and organization for the patients 
(unlike HVLT-R where the individuals are required to organize information in order to 
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encode more effectively), so the frontal lobes may not be involved the same way as they 
are with HVLT-R. Therefore, if the patients are able to encode the information more 
effectively due to the inclusion of a context, this will not be one of the factors 
contributing to the delayed memory and retention performances. Therefore, the 
improvements observed at the level of immediate memory, delayed memory and 
retention may be a function of the pomegranate acting upon the hypoxic states early 
postoperatively. For the placebo group, we observe a relatively flat (slightly declined) 
immediate memory which may be translating into relatively flat scores for both delayed 
memory and retention. It is important to note that visuospatial functioning could also 
impact their ability to encode and remember the information. Therefore, poor visuospatial 
functioning could be contributing to the lower scores for the placebo group. However, it 
is important to note that both groups only had two individuals in each group due to the 
discontinuation of the test later on in the study.  
Brief Visuospatial Memory Test-Revised 
Placebo and treatment groups had no significant declines or improvements from 
baseline to time 2, time 2 to time 3 or time 1 to time 3 on any of the components of 
memory. Illustrations of BVMT performance, however, also noted variability in the 
patterns of the components of memory. For both immediate and delayed memory, an 
increase is observed for both groups from time 1 to time 2. However, as mentioned 
previously, both groups are performing significantly below average at time 1; therefore, 
the better performances may be a function of regression to the mean. However, it is 
important to note that the treatment group has a sharper increase for delayed memory 
compared to the placebo group. When observing their learning scores, we see that the 
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treatment group has a relatively flat learning from time 1 to time 2 (unlike HVLT-R 
where we are seeing declines in learning which may be affecting their memory). So it can 
be suggested that when learning is stable from time 1 to time 2 (they are encoding as 
much information at time 2 as they are during time 1), the increases in delayed memory, 
and subsequently retention, can be a function of the pomegranate workings in the early 
postoperative period.  Furthermore, we see that although the placebo group has better 
performances in learning and immediate memory from time 1 to time 2, they are unable 
to retain the learned information to the level that the treatment group is retaining.  
 
Comment on Test Characteristics  
We observe that while the treatment group has lower performances on BVMT, 
they have higher performances on the RCFT compared to the placebo group. This is an 
unexpected finding given that both of these tests are assessing visual memory and we 
would expect the pattern of each group’s performances to be the same within each task. 
However, this task is different from the previous described visual memory measure 
(RCFT) in several ways. First, the RCFT is a task that has a contextual component to it 
(which can assist in learning as it is already organized and doesn’t require the individuals 
to put in effort in doing so), while the BVMT does not. The RCFT has one complex 
figure, while the BVMT has multiple simple figures. Moreover, the BVMT has a time 
and learning component (each patient is administered multiple trials of the same figures), 
while the RCFT does not (the stimulus is presented on only one trial). It is important to 
note that although the trials of learning is to facilitate the encoding process, if the patients 
are having difficulties with attention and become overwhelmed by the amount of 
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information presented in 10 seconds, learning will not be facilitated despite the multiple 
trials. Furthermore, comparing HVLT-R and BVMT (which are both assessing learning 
and memory), treatment group performances demonstrate declining learning for HVLT 
and a slight increase on BVMT suggesting that the organizational component of HVLT 
may be impacting learning and subsequently memory. However, the lack of decline on 
BVMT suggests that there may be an effect of the pomegranate on learning when the task 
is not heavily relying on the frontal lobe.  
 
Comment on Individual Measures 
 Given all the variability, it appears that the declines and improvements on the 
individual measures may be canceling each other out when composites are created, 
thereby washing out statistically detectable differences in the composites. However, it is 
important to note that retention was one component of memory that was consistently 
better for the treatment group than the placebo group on almost all of the tests (except 
HVLT-R). Retention is a score that takes into account both the individual’s immediate 
memory and delayed memory. This is the most informative measure of an individual’s 
memory, as it represents how much an individual remembers relative to how much was 
initially learned.  Therefore, even if an individual’s learning and immediate memory is 
poor, retention reflects more directly how much information is remembered. The 
differences observed in retention may best reflect differences between groups and 
possibly may be the most informative variable to provide support for the impact of 
pomegranate on memory. 
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 Overall, examination of the various memory tests suggest that the patients in the 
treatment group are performing better from time 1 to time 2 on non-verbal measures 
(indicative of involvement of the right hemisphere) compared to the verbal measures 
(indicative of involvement of the left hemisphere). Therefore, it is suggestive that 
pomegranate is more beneficial for dealing with the hypoxic effects of the right 
hemisphere than the left hemisphere. This could be explained by animal studies that have 
examined the effects of hypoxia on the left and right hemisphere. Studies have shown 
that the neurochemical activity in the right hemisphere is more susceptible to the effects 
of hypoxia (Nalivaeva et al., 1995; Nalivaeva, Klementev, Plesneva, Chekulaeva & 
Zhuravin, 1998).  
 
Comment on Outliers  
 In order to determine whether the patterns of performances were being driven by 
outliers, a thorough examination of the data points was conducted. Data points that were  
+/- 3 standard deviations were considered to be outliers. Given that the RCFT only had 
two individuals in each group, outliers were not removed from this test. Logical Memory 
had no outliers. One individual data point was removed from BVMT delayed memory 
and several outliers were removed from HVLT-R delayed memory, retention and 
recognition. Although the pattern of BVMT delayed memory did not change once the 
outlier was removed, HVLT-R patterns changed once the outliers were removed. 
Although the treatment group’s pattern of performance does not change much from 
Figure 11 (Delayed Memory), the placebo group improves from time 1 to time 2. This 
follows the patterns observed on other tests which support that this group may have a 
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high cognitive reserve which could be protective of cognitive declines. The continued 
decline of the treatment group from time 1 to time 2 may be due to a more severe disease 
state (therefore, more compromised cognitive functions) compared to the placebo group 
as they present with a higher frequency of individuals with vascular risk factors. 
However, the relative stability of performances from time 2 to time 3 for the treatment 
group and declines for the placebo group may be a function of the pomegranate 
workings. With regards to retention, the placebo group increases from time 1 to time 2; 
however, the treatment group decreases from time 1 to time 2. As mentioned above, this 
could be due to the differences in the severity of disease states and cognitive reserve. In 
contrast, from time 2 to time 3, the treatment and placebo groups decrease slightly. 
Recognition patterns show the treatment group and placebo group declining from time 1 
to time 2. However, the placebo group shows greater improvements from time 2 to time 3 
while the treatment group increases slightly.  
 
Incidence of Impairments/Improvements 
 Patients’ performances were examined individually in order to determine the 
incidence of memory impairments and/or improvements. First, their composite 
performances were compared to their previous performances (e.g. time 1 to time 2, time 2 
to time 3, and time 1 to time 3) by creating a change z-score. Using the one standard 
deviation method, it was determined that there was no significant difference between the 
groups in the number of instances of clinical memory impairments or improvements at 
each time point. This may be a function of the limitations of this study which will be 
addressed later (e.g. sample size). Second, since a couple of these tests did not have 
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alternate forms, measures were examined individually while controlling for practice 
effects using reliable change indices. The highest incidence of clinical memory 
impairments (1.65 standard deviations below the mean) was observed in the placebo 
group from time 1 to time 2 (e.g., more patients were impaired on several tests of 
memory). However, from time 2 to time 3 and time 1 to time 3, the placebo and treatment 
groups did not differ significantly from each other (e.g. similar instances of memory 
impairments). This again demonstrates the protective effects of pomegranate early after 
surgery. Although there was a higher incidence of memory impairments across the tests, 
it is important to note that there were two individuals in the treatment group and three 
individuals in the placebo group with impairments from time 1 to time 2. Notably, the 
two impaired individuals in the treatment group performed poorly on tasks that required 
them to learn and encode the information, which are considered frontal lobe functions. 
Although all memory tests require learning and encoding of information, there are certain 
tests (e.g., Logical Memory and RCFT) that are contextual by design and do not require 
the individual to create context or organization in order to efficiently learn the 
information. Despite being potentially more impaired, we do not observe the declines 
expected on executively-demanding tasks in those with such risk factors and frontal 
dysfunction. The relative lack of decline may reflect some protection from pomegranate.  
 
Limitations 
There were a few limitations to this study that should be considered.  First, the 
sample size was very small especially since the goal of this study examined the difference 
between two groups. This limited the power of the study and led to an inability to detect 
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statistical significance. The chosen tests at the initial start of the study may not have been 
the most useful in determining the effects of pomegranate on memory as they did not 
have alternate forms; therefore, leading to possible effects of practice. This in turn may 
have compromised the reliability of the composites. Due to the limited sample size, we 
were unable to examine the effects of covariates (e.g. demographics, medical variables, 
surgical variables) on the results. Additionally, given the research on frontal dysfunction 
of patients with vascular risk factors, it would have been useful to control for frontal lobe 
functions in order to determine whether frontal dysfunction may be affecting temporal 
lobe functioning. Additionally, it would have helped to have certain surgical variables, 
such as cerebral oxygen desaturation (Slater et al., 2009), that examine hypoxia or 
ischemia in order to support the idea that pomegranate is indeed protecting the 
hippocampus from hypoxia. Another limitation was that we were unable to track their 
diet (e.g. fruits/vegetable servings each day in order to ascertain the amount of 
antioxidants they intake), compliance with the pills, and exercise or activity level of these 
patients. Moreover, an analysis of their urine could have helped to confirm the amount of 
antioxidants they were taking in.  
 
Future Research and Treatment 
 Although there are several limitations to this pilot study, it provides direction for 
future research and treatment. Results of this study suggest that there is some effect of 
pomegranate in the early postoperative period after cardiac surgery. Given all the 
variables and components of memory measured in this study, it appears that examination 
of retention rates will yield the most informative results for future studies. It has been 
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noted that “there is only one memory system but there are multiple processes operating 
on this system or multiple ways of accessing its contents” (Squire, 2004). Given what we 
now know about the possible factors affecting memory functioning, a similar study 
should be conducted on a much larger scale and over a longer period of time, 
incorporating various perioperative variables (e.g. hypoxia, ischemia), individual 
differences (e.g. cognitive reserve) and other cognitive functions (e.g. frontal lobe 
functions). Furthermore, future studies should compare the effects of pomegranate on the 
memory functioning of patients with CAD or valvular disease (without cardiac surgery) 
and those with cardiac surgery in order to further understand the mechanisms of 
pomegranates within these disease states. It would also be helpful to correlate the results 
of cognitive tests with brain imaging before and after cardiac surgery in order to locate 
where the most damage is present before and after surgery and where any improvement is 
occurring in the brain after pomegranate supplementation.  
 
Implications 
 Although the treatment and placebo groups are performing similarly at time 3, the 
critical time period of interpatient variability seems to be from time 1 to time 2. The most 
important implication for patients is that if we are able to offset the amount of memory 
decline immediately after surgery, then their long term prognosis may be better- 
according to a previously mentioned study by Newman et al. (2001). Alternatively, there 
are important implications for both patients and healthcare personnel. Research has 
shown that there are several factors that predict prolonged intensive care and length of 
hospital stay, including intraoperative cerebral oxygen desaturation (Slater et al., 2009). 
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If pomegranate is indeed targeting hypoxic mechanisms, then it may lead to shorter 
intensive care unit and hospital stays, thereby decreasing hospital costs and costs to the 
healthcare system. Another general implication for individuals is to increase engagement 
in health behaviors that are easily incorporated into daily life, are relatively free of 
negative side effects, and are comparatively inexpensive, in order to limit the number of 
factors (e.g., hypertension, high cholesterol and smoking) which put them at greater risk 
for heart disease necessitating cardiac surgery and the subsequent cognitive decline that 
commonly occurs after cardiac surgery. Ultimately, continued research conducted in a 
similar vein would lead to better treatments that improve the outcome of cardiac surgery 
and the cognitive well-being of the multitude of men and women who undergo these 
types of surgeries.   
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